2021 AAN Annual Meeting Science Program by American Academy of Neurology

April 17 – April 22

Science Program

AAN Excellence— Delivered Unconventionally

Make KESIMPTA your 1st choice Learn more at KesimptaHCP.com

KESIMPTA and the KESIMPTA logo are registered trademarks of Novartis AG.

Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, New Jersey 07936-1080

2/21

T-KSM-1401237

CONTENTS Introduction

What’s New in the 2021 Science Program Registration

2 4

Programming Program Glossary Meeting-at-a-glance Plenary Sessions Neuroscience in the Clinic Invited Science Scientific Sessions Posters Abstracts of Distinction Exclusive Virtual Gold Programs by Topic

6 7 15 22 30 32 49 55 58

Prepare for your virtual Annual Meeting experience: 1. Register at AAN.com/21AM 2. Block your calendar for April 17-22 to be sure to participate in the live Q&A sessions 3. Share what you’re excited about using #AANAM Remember: Your registration includes access to sessions for 30 days after the conference.

The information and preliminary program details presented in this booklet are accurate as of February 23, 2021, and subject to change. Schedule is listed in Eastern Time. Please visit AAN.com/21AM for the most up-to-date information and more programming details. AAN.com/21AM 1

AAN EXCELLENCE—DELIVERED UNCONVENTIONALLY

It’s time to get excited about the upcoming AAN Annual Meeting Science Program! To address the time demands of virtual programming, we trimmed the number of scientific sessions, but kept all the key elements of the program—most importantly, the Plenaries, Neuroscience in the Clinic, and the Invited Science sessions will once again be front and center. In addition to the cutting-edge original science, this year’s program also brings into focus some of the most relevant issues of our times, such as neurologic complications of COVID-19, the effects of the pandemic on the field of neurology, health care disparities, and the neurologic sequelae of systemic racism.

A special bonus to being able to see each other virtually is that so many of our friends and colleagues, who otherwise would not have been able to travel across the world, will now be able to join us at the click of a button! This makes the 2021 #AANAM a truly global meeting—accessible, equitable, and indispensable to neurologists and neuroscientists everywhere. I am looking forward to coming together as a community that is fueled by science!

Natalia S. Rost, MD, MPH, FAAN, FAHA Chair, Science Committee

2 2021 AAN Annual Meeting

Annual Meeting Science is...

ROBUST. IMPACTFUL. INCLUSIVE. CUTTING-EDGE. 2000+ Abstracts 26 Topics

Authors from 50+ countries Including the newly added Health Care Disparities which features 20+ abstracts

Additional Emerging Science abstracts announced during the Annual Meeting on timely research conducted after October 2020

Join during the scheduled program time for live Q&As with authors, including interactive chat formats. The virtual format provides even greater opportunity to pick the brain of the top minds in neurology!

Browse Abstracts On the following pages, you’ll find a preview of the 2021 AAN Annual Meeting Science Program, organized by program type. To find a database of complete abstracts, searchable by title, author last name, author institution, and topic, visit https://index.mirasmart.com/AAN2021. Emerging Science abstracts will be available April 17, 2021, at 12:01 a.m. ET. AAN.com/21AM

REGISTRATION There are two ways to experience the AAN Annual Meeting.

Virtual Registration Your Virtual Registration for the Annual Meeting includes access to live streaming and recorded sessions for 30 days after the conference. This exceptional value includes: All the CME You Need for the Year 90+ expert-led education courses

Access to program syllabi and slides

2,000+ scientific abstracts presented in multiple formats

Q&As with presenters and abstract authors during scheduled session time slots—attend live to join the conversation

7 Plenary Sessions featuring leaders in neurology Experiential Learning Area Talks

Networking Opportunities 15+ scheduled networking events Nightly fun and entertainment

Ability to create your own oneon-one and small group chat sessions

5+ public networking areas

Access to AAN and Industry Resources AAN products and services showcase Virtual Exhibit Hall Industry Therapeutic Updates

Virtual Gold Registration

Best Value

Upgrade to Virtual Gold Registration for the best value with extended access and additional courses through March 31, 2022, with Annual Meeting On Demand. In addition to all of the benefits of Virtual Registration, you’ll retain access to all meeting syllabi and virtual session recordings, CME, and receive exclusive access to more than 25 bonus sessions and presentations to round out this comprehensive digital reference library accessible anytime, anywhere. See page 58 for the list of programs included in Virtual Gold Registration. 4 2021 AAN Annual Meeting

Deadline Online

Online Phone

AAN.com/21AM

AAN.com/view/21AM (800) 676-4226 (US/Canada) (415) 979-2283 (International)

Registration Rates Member Type

Early Rates

Standard Rates

Through March 25, 2021

March 26 - April 22, 2021

Virtual Virtual Gold

Student Member

$79

Honorary or Senior Member

$239

Junior or Intern Member

$210

$289

$250

$329

Non-physician Member*

$375

$544

$445

$614

Neurologist or Physician Affiliate Member

$525

$764

$630

$869

Nonmember

$750

$1,129

$900

$1,279

*Non-physician member includes Business Administrator, Researcher, and Advanced Practice Provider member types.

All sales for online programs including virtual conferences are final, nonrefundable, and nontransferable. Registration includes access to programs and materials on demand after the end of the conference.

Become an AAN member today for registration discounts. Visit AAN.com/membership.

Protect yourself from fraudulent companies. Convention Management Resources (CMR) is the official registration partner of the AAN. Kenes Group is the official virtual platform provider of the 2021 Annual Meeting. AAN.com/21AM

PROGRAM GLOSSARY The Annual Meeting offers six days of programming for neurologists and neuroscience professionals at every career stage. Use this glossary to get information at-a-glance to help you quickly find items of interest to you. Programs

All Annual Meeting programs are color-coded. Many programs are indicated by one of the letter codes below, followed by sequential numbers, to help you spot a specific program quickly.

C = Course

An education program using one or more teaching methods, including didactic, interactive, and case-based.

N = Neuroscience in the Clinic Session

A session featuring a mix of scientists and clinicians actively engaged in lively case discussion to integrate scientific research with clinical application. Scientists will provide background on a case and clinicians will apply the case to a patient. Sessions will feature abstract presentations related to the topic and end with a panel discussion.

S = Scientific Session A group of abstracts covering a similar topic presented in an oral format. Hear a total of five abstracts presented during each sessions with interactive audience Q&A after the second and fifth abstracts are presented. = Experiential Learning Area

An interactive way of learning that will engage you intellectually, emotionally, and socially and offer you fresh ideas to help you personally and professionally.

Plenary Session

A premier session highlighting the latest advances in neuroscience presented by some of the most cutting-edge and well-known thought leaders in the field of neurology.

Poster Session

A series of thematic abstract presentations. These will be available in 26 different topics during the Annual Meeting, where you will have the opportunity to interact with authors virtually.

Symbols & Icons

CME

= CME Credits Offered

Emerging Science The Emerging Science program highlights the most current research being done in the field of neurology. Abstracts qualify for Emerging Science presentations by having key aspects of research conducted after the October 2020 abstract submission deadline and must be new and of sufficient scientific importance to warrant expedited presentation and publication. These previously unpublished abstracts contain timely, significant, and innovative content. Look for more information, including abstract titles, on AAN.com/21AM in mid-March about these sessions with full Emerging Science abstracts becoming available during the Annual Meeting. 6 2021 AAN Annual Meeting

C = Course

S = Scientific Session

= Experiential Learning Area

SAT April 17 Posters Networking and Engagement

Exhibit Hall

Experiential Learning Areas

Frontiers in Neuroscience Plenary Session

The following pages provide a high-level look at when the various types of programming 8:00 a.m. ET will be offered. Programming is in Eastern Time, which offers the most flexibility for US and international 9:00 a.m. ET attendees. For the best experience, tune in during the scheduled time to participate in Q&As, networking, and other interactive components 10:00 a.m. ET of the conference. The program schedule is subject to change; visit AAN.com/2021Program for the most up-to-date information.

11:00 a.m. ET

12:00 p.m. ET

C1 8:00 a.m.–2:00 p.m. ET

C2 8:00 a.m.–5:00 p.m. ET

C3–C5 9:00 a.m.–10:00 a.m. ET

C6–C8

Networking and Engagement

Industry Therapeutic Updates

1:00 p.m. ET

S1–S3

Neuroscience in the Clinic

2:00 p.m. ET

12:00 p.m.–1:00 p.m. ET

C9–C11 2:00 p.m.–3:00 p.m. ET

C12 2:00 p.m.–5:00 p.m. ET

C13–C17 4:00 p.m.–5:00 p.m. ET

Hot Topics: Neuro - COVID Plenary Session

Networking and Engagement

3:00 p.m. ET

S4–S6

4:00 p.m. ET

Experiential Learning Areas

5:00 p.m. ET

6:00 p.m. ET

Networking and Engagement

7:00 p.m. ET

8:00 p.m. ET

AAN.com/21AM

MEETING-AT-A-GLANCE SUN April 18 8:00 a.m. ET

9:00 a.m. ET

Posters

C18–C22

Exhibit Hall

Networking and Engagement

10:00 a.m. ET

Industry Therapeutic Updates

Experiential Learning Areas

Presidential Plenary Session

11:00 a.m. ET

12:00 p.m. ET

1:00 p.m. ET

2:00 p.m. ET

Networking and Engagement

Industry Therapeutic Updates

S7–S9

Experiential Learning Areas

C23–C27 2:00 p.m.–3:00 p.m. ET

C28 3:00 p.m. ET

4:00 p.m. ET

5:00 p.m. ET

Networking and Engagement

2:00 p.m.–6:30 p.m. ET

S10–S12

C34–C38

C29–C33 4:00 p.m.–5:00 p.m. ET 6:00 p.m.–7:00 p.m. ET

Neuroscience in the Clinic

6:00 p.m. ET

7:00 p.m. ET

Networking and Engagement

8:00 p.m. ET

8 2021 AAN Annual Meeting

Industry Therapeutic Updates

C = Course

= Experiential Learning Area

S = Scientific Session

MON April 19 Posters

8:00 a.m. ET

C39–C42

Exhibit Hall

Networking and Engagement

Industry Therapeutic Updates

9:00 a.m. ET

Experiential Learning Areas 10:00 a.m. ET

Contemporary Clinical Issues Plenary Session

11:00 a.m. ET

12:00 p.m. ET

Networking and Engagement S13–S15

Networking and Engagement S16–S18

Industry Therapeutic Updates C43

(Health Care Equity Symposium) 1:00 p.m.–3:00 p.m. ET

1:00 p.m. ET

Experiential Learning Areas Neuroscience in the Clinic

2:00 p.m. ET

3:00 p.m. ET

C44–C47 2:00 p.m.–3:00 p.m. ET

C48

4:00 p.m. ET

2:00 p.m.–6:00 p.m. ET

C49 2:00 p.m.–6:30 p.m. ET 5:00 p.m. ET

C50–C53 4:00 p.m.–5:00 p.m. ET

C54–C58 6:00 p.m.–7:00 p.m. ET

Networking and Engagement

6:00 p.m. ET

Industry Therapeutic Updates

7:00 p.m. ET

8:00 p.m. ET

AAN.com/21AM

MEETING-AT-A-GLANCE TUE April 20 8:00 a.m. ET

9:00 a.m. ET

Posters

C59–C62

Exhibit Hall

Networking and Engagement

10:00 a.m. ET

Industry Therapeutic Updates

Experiential Learning Areas

Clinical Trials Plenary Session

11:00 a.m. ET

12:00 p.m. ET

1:00 p.m. ET

Networking and Engagement

2:00 p.m. ET

S19–S22

Industry Therapeutic Updates

Inspirational Talk with Alison Levine

C63–C67 2:00 p.m.–3:00 p.m. ET

C68–C71 3:00 p.m. ET

4:00 p.m. ET

5:00 p.m. ET

Networking and Engagement

4:00 p.m.–5:00 p.m. ET

C72–C76 6:00 p.m.–7:00 p.m. ET

S23–S25

Neuroscience in the Clinic

6:00 p.m. ET

7:00 p.m. ET

Networking and Engagement

8:00 p.m. ET

10 2021 AAN Annual Meeting

Industry Therapeutic Updates

Experiential Learning Areas

C = Course

= Experiential Learning Area

S = Scientific Session

WED April 21 Posters

Networking and Engagement

8:00 a.m. ET

C77–C80

Exhibit Hall

Industry Therapeutic Updates

9:00 a.m. ET

Experiential Learning Areas 10:00 a.m. ET

Controversies in Neurology Plenary Session

11:00 a.m. ET

12:00 p.m. ET

Networking and Engagement S26–S28

Industry Therapeutic Updates

Neuroscience in the Clinic

1:00 p.m. ET

Experiential Learning Areas 2:00 p.m. ET

C81–C84 2:00 p.m.–3:00 p.m. ET

C85–C88 Networking and Engagement

4:00 p.m.–5:00 p.m. ET

3:00 p.m. ET

C89–C92 6:00 p.m.–7:00 p.m. ET

S29–S32

4:00 p.m. ET

Neuroscience in the Clinic

5:00 p.m. ET

6:00 p.m. ET

7:00 p.m. ET

8:00 p.m. ET

AAN.com/21AM

MEETING-AT-A-GLANCE THU April 22

Prepare for your virtual Annual Meeting experience:

8:00 a.m. ET

1. Register at AAN.com/21AM

9:00 a.m. ET

10:00 a.m. ET

Networking and Engagement

2. Block your calendar for April 17-22 to be sure to participate in the live Q&A sessions

Experiential Learning Areas

3. Share what you’re excited about using #AANAM Remember: Your registration includes access to sessions for 30 days after the conference.

Neurology Year in Review Plenary Session

11:00 a.m. ET

12:00 p.m. ET

1:00 p.m. ET

Experiential Learning Areas 2:00 p.m. ET

Live Inspirational Talk with Bestselling Author, Adventurer Alison Levine Alison Levine, the first American Women's Everest Expedition team captain and New York Times bestselling author of On the Edge: Leadership Lessons from Everest and Other Extreme Environments, will inspire Annual Meeting attendees on Tuesday, April 20, from 1:00 p.m.–2:00 p.m. ET. Her talk “On the Edge: The Art of High-Impact Leadership” will focus on the importance of teamwork, determination, tenacity, and the ability to adapt to changing environments as the critical keys to success in one’s life and career. She will draw on her experience as team captain to make a compelling case that the leadership principles that apply in the world of extreme adventure also apply to today’s rigorously competitive work environments. Be sure to stay after the 45-minute talk for a question and answer session.

VIS .exp w w w

h.c o n e r

CE A P L S CE A U RT E R I E N E S I V A XP Y SID E O T AN H M T H E O F nO

COMMITTED TO ADVANCING THE SCIENTIFIC UNDERSTANDING OF

NEUROGENIC ORTHOSTATIC HYPOTENSION (nOH)

CONNECTING IN

SPECTACULAR

WAYS

The power of connection is more evident than ever before. The 2021 Annual Meeting will be packed with innovative virtual opportunities for socializing, networking, and entertainment, including nightly events and networking lounges available three times each day on different topics to engage in casual conversation.

Nightly Events 7:00 p.m.–8:00 p.m. ET

Saturday, April 17: Celebrity Entertainment

Sunday, April 18: Fun & Games

Tuesday, April 20: AAN Talent Show

Monday, April 19: Interactive Experiences

Learn more at AAN.com/21AM.

PLENARY SESSIONS Frontiers in Neuroscience Plenary Session Saturday, April 17

CME

10:00 a.m.–12:00 p.m. ET

This plenary session features basic and translational research related to clinical issues of importance. Hear from five outstanding speakers as they summarize their recent research finding and dive into the clinical implications of the results.

FRONTIERS IN NEUROSCIENCE PLENARY SESSION

MODERATOR Paul M. George, MD, PhD, MSE, Stanford, CA

Dissecting the Control of Blood Flow Through Brain Capillaries Andy Shih, PhD, Seattle, WA

Organization and Control of Hippocampal Circuits

Decoding Speech Cortex

Edward Chang, MD, San Francisco, CA

Ivan Soltesz, PhD, Stanford, CA

Microtubules in Health and Disease Antonina Roll-Mecak, PhD, Bethesda, MD

Stem Cell Therapy for Spinal Cord Injury: Transition to the Clinic Mark H. Tuszynski, MD, PhD, FAAN, La Jolla, CA

AAN.com/21AM

PLENARY SESSIONS Hot Topics: Neuro-COVID Plenary Session Saturday, April 17

CME

5:00 p.m.–7:00 p.m. ET

For the first time, the 2021 Hot Topics Plenary Session will focus entirely on one important issue, the global COVID-19 pandemic. Join the keynote address with Walter J. Koroshetz, MD, FAAN, and Anthony S. Fauci, MD, who have been at the forefront of the public health crisis. Four outstanding speakers will then summarize their COVID-19-related research findings and describe the clinical implications of their work.

HOT TOPICS: NEURO-COVID PLENARY SESSION

Keynote Address

MODERATORS Walter J. Koroshetz, MD, FAAN, Bethesda, MD

Natalia S. Rost, MD, MPH, FAAN, FAHA, Boston, MA Chair, AAN Science Committee Paul M. George, MD, PhD, MSE, Stanford, CA Vice Chair, AAN Science Committee

Anthony S. Fauci, MD, Bethesda, MD

Biology/Acute Illness of COVID-19 Sherry Chou, MD, MMSc, FNCS, Pittsburgh, PA

COVID-19 Disparities: An Urgent Long-term Neurologic Vaccine and Immunological Call to Dismantle Structural Consequences of COVID-19 Response Racism and Prioritize Justice Serena Spudich, MD, MA, Igor Koralnik, MD, FAAN, Nicte I. Mejia, MD, MPH, FAAN, Boston, MA

16 2021 AAN Annual Meeting

New Haven, CT

Chicago, IL

Presidential Plenary Session Sunday, April 18

CME

2.25

10:00 a.m.–1:00 p.m. ET

This session features the AAN’s premier lecture awards for clinically relevant research and a presentation by a leading lecturer. Top researchers speak on some of the most significant findings in neurology in 2021. AAN President James C. Stevens, MD, FAAN, will kick off the session with a presentation of the 2020 President’s Award and Presidential Lecture. After that, tune in for a live address from AAN Chief Executive Officer Mary Post, MBA, CAE, followed by a few words from AAN President Elect Orly Avitzur, MD, MBA, FAAN. Session moderators will then introduce this year's list of superb lecturers.

PRESIDENTIAL PLENARY SESSION

MODERATOR Natalia S. Rost, MD, MPH, FAAN, FAH, Boston, MA Chair, AAN Science Committee

Presidential Lecture: Disruption: How to Pivot From Uncertainty to Success—The AAN Story

H. Houston Merritt Lecture: Where’s the Vision? The Importance of Visual Outcomes in Neurological Disease

James C. Stevens, MD, FAAN, Fort Wayne, IN President, American Academy of Neurology

Steven Galetta, MD, FAAN, New York, NY

Sidney Carter Award in Child Neurology: Gene Therapy Fulfills the Promise for Kids with Neuromuscular Disease

Robert Wartenberg Lecture: Preventing Parkinson's Disease—The Road Forward

Jerry R. Mendell, MD, FAAN, Columbus, OH

Caroline Tanner, MD, PhD, FAAN, San Francisco, CA

AAN.com/21AM

PLENARY SESSIONS

Contemporary Clinical Issues Plenary Session Monday, April 19

CME

2.5

10:00 a.m.–12:30 p.m. ET

CONTEMPORARY CLINICAL ISSUES PLENARY SESSION

This session highlights issues most critical to practicing neurologists, including abstracts related to new therapeutic developments, clinical applications of basic and translational research, and innovative technical developments. The first three topics will be introduced by presenters followed by a commentary from the discussant. The second half of the session will feature standalone talks on various topics. PRESENTER

DISCUSSANT

MODERATOR Peter Goadsby, MD, PhD, Los Angeles, CA Member, AAN Science Committee

Long-term Survival of Participants in the CENTAUR Trials of AMX0035 for ALS P: Sabrina Paganoni, MD, PhD, Boston, MA D: Timothy M. Miller, MD, PhD, St. Louis, MO

PRESENTER

DISCUSSANT

PRESENTER

DISCUSSANT

Prevalence of White Matter Neuroimmunology Adverse Events Associated with Immune Checkpoint Inhibitor: Hyperintensities in a Population aged ≤50 both With and Without Mild Traumatic A Retrospective, Pharmacovigilance Study Brain Injury Using FAERS Database P: Takahisa Mikami, MD, New York, NY D: Karin Woodman, MD, Houston, TX

Stem Cell Tourism/ Regenerative Medicine Sean I. Savitz, MD, Houston, TX

P: Teena Shetty, MD, New York, NY D: Jack Tsao, MD, DPhil, FAAN, Bethesda, MD

Gene Therapy for Childhood Neuromuscular Syndromes Perry Shieh, MD, PhD, FAAN, Los Angeles, CA

18 2021 AAN Annual Meeting

Daylights Savings Time: Is There a Controversy? Phyllis Zee, MD, PhD, Chicago, IL

Clinical Trials Plenary Session Tuesday, April 20

CME

2.5

10:00 a.m.–12:30 p.m. ET

This session covers important clinical topics identified from other society meetings that affect patient care. The latest updates within several clinical trials conducted over the course of the last year will be presented.

Deborah Hall, MD, PhD, FAAN, Chicago, IL Member, AAN Science Committee Holly E. Hinson, MD, MCR, FAAN, Portland, OR Member, AAN Science Committee

ESCAPE-NA1 (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischemic Stroke) Michael Tymianski, MD, PhD, FRCSC, Toronto, ON, Canada

Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Preventive Treatment of Migraine

Efficacy and Safety of LowerSodium Oxybate in a Phase 3, Placebo-Controlled, DoubleBlind, Randomized Withdrawal Study in Adult Participants with Idiopathic Hypersomnia

Jessica Ailani, MD, FAAN, McLean, VA

Yves Dauvilliers, MD, PhD, Montpellier, France

Sustained Benefits for 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy—Six Month Results from a Multicenter Randomized Controlled Trial

Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Disease

Raúl Martínez-Fernández, MD, PhD, Madrid, Spain

Efficacy, Safety, and Tolerability of Efgartigimod in Patients with Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study James F. Howard, Jr., MD, FAAN, Chapel Hill, NC

Efficacy and Safety Results of the Avalglucosidase Alfa Phase 3 COMET Trial in Late-onset Pompe Disease Patients Hani Kushlaf, MD, FAAN, Cincinnati, OH

Erika A. Petersen, MD, FAANS, FACS, Little Rock, AR AAN.com/21AM

CLINICAL TRIALS PLENARY SESSION

MODERATORS

PLENARY SESSIONS Controversies in Neurology Plenary Session

CME

2.25

Wednesday, April 21 10:00 a.m.–12:30 p.m. ET

CONTROVERSIES IN NEUROLOGY PLENARY SESSION

This session features experts discussing the most current and controversial issues in neuroscience. Tune in for a scholarly debate between two expert speakers, each advocating for one side of a single topic, followed by a rebuttal.

MODERATORS Martinson K. Arnan, MD, Kalamazoo, MI Member, AAN Science Committee Amy R. Brooks-Kayal, MD, FAAN, Sacramento, CA Member, AAN Science Committee

YES

Teleneurology: Can It Replace In-person Visits?

Y: Tamika M. Burrus, MD, FAAN, Santa Monica, CA N: Amy Guzik, MD, Winston-Salem, NC

YES

Should Amyloid Continue to be Targeted in Alzheimer’s? Y: Jeffrey Lee Cummings, MD, FAAN, Las Vegas, NV N: Mary Sano, PhD, New York, NY

20 2021 AAN Annual Meeting

YES

Shattering the Clock: Should There Be a Time Window for Acute Stroke Intervention?

Y: Maarten G. Lansberg, MD, Stanford, CA N: Jeffrey L. Saver, MD, FAAN, Los Angeles, CA

Neurology Year in Review Plenary Session Thursday, April 22

CME

2.5

10:00 a.m.–12:30 p.m. ET

This session looks back at the past year of research, highlighting some of the most relevant strides made in neurology subspecialties, including movement disorders, stroke, and headache. One speaker will examine a topic of particular interest that will examine how we diversify the neurology workforce.

Fernando Testai, MD, PhD, Chicago, IL Member, AAN Science Committee

Epilepsy Seizure Detection and Device Intervention Kathryn A. Davis, MD, Philadelphia, PA

Emerging Therapies for Pediatric Metabolic Disorders

Diversification of the Neurology Workforce

Bruce Ovbiagele, MD, MSc, FAAN, San Francisco, CA

Stroke Recovery

Heidi M. Schambra, MD, New York, NY

Therapeutics in Movement Disorders Irene Malaty, MD, FAAN, Gainesville, FL

Headache

Rashmi Halker-Singh, MD, FAAN, Scottsdale, AZ

Marc C. Patterson, MD, FAAN, FRACP, Rochester, MN AAN.com/21AM

NEUROLOGY YEAR IN REVIEW PLENARY SESSION

MODERATOR

NEUROSCIENCE IN THE CLINIC

NEUROSCIENCE IN THE CLINIC SESSIONS

Neuroscience in the Clinic Sessions feature a mix of scientists and clinicians actively engaged in lively case discussion to integrate scientific research with clinical application. Scientists will provide background on a case and clinicians will apply the case to a patient. Tune in to hear abstract presentations related to the topic and each session will end with a live panel discussion with questions from the audience.

Neuroscience in the Clinic: Neurobiological Consequences of Racism on Health Outcomes

Saturday, April 17 2:00 p.m.–4:00 p.m. ET

Directors:

CME

Jessica Robinson Papp, MD, FAAN, New York, NY Temitayo Oyegbile, MD, PhD, Sacramento, CA

Description: Racism can affect health in many ways, including disparities in access to care, poverty,

and social exclusion. However the direct experience of racism is also a contributor to adverse health outcomes; this is the focus of this session. Faculty will present research on how the experience of racism might affect brain structure and function, and how resultant changes in autonomic nervous system function can affect health outcomes, such as cardiovascular morbidity.

2:00 p.m.–2:15 p.m. ET 3:30 p.m.–3:45 p.m. ET » Introduction and Case Presentation » Abstract: Associations Between Access to Health Care and Race in Cardiac Arrest Temitayo Oyegbile, MD, PhD, Sacramento, CA Survivors During the COVID-19 Pandemic 2:15 p.m.–2:45 p.m. ET Lia Farrell, New York, NY » Neural Correlates of Social Discrimination 3:45 p.m.–4:00 p.m. ET Uraina Clark, PhD, New York, NY » Moderated Q&A and Panel Discussion 2:45 p.m.–3:15 p.m. ET Jessica Robinson Papp, MD, FAAN, New York, NY » Perceived Discrimination, Heart Rate Variability, and Cardiovascular Outcomes Julian Thayer, PhD, Irvine, CA 3:15 p.m.–3:30 p.m. ET » Abstract: Allostatic Load Predicts Racial Disparities in Post Intracerebral Hemorrhage Cognitive Outcomes Jennifer Harris, MD, New York, NY

22 2021 AAN Annual Meeting

Neuroscience in the Clinic: The Neurology of Obesity Sunday, April 18

Directors:

CME

5:00 p.m.–7:00 p.m. ET

Riley Bove, MD, San Francisco, CA Deborah Gustafson, MS, PhD, Brooklyn, NY

Description: The epidemic of obesity has resulted in a host of physiological changes—vascular,

5:00 p.m.–5:10 p.m. ET » Case Presentation: An Obese Patient with TIA Ilana B. Katz Sand, MD, New York, NY Satya Dash, MD, PhD, Toronto, ON, Canada 5:10 p.m.–5:30 p.m. ET » The Neuroepidemiology of Obesity Deborah Gustafson, MS, PhD, Brooklyn, NY 5:30 p.m.–5:50 p.m. ET » Genetics of Body Weight Regulation Satya Dash, MD, PhD, Toronto, ON, Canada 5:50 p.m.–6:00 p.m. ET » Clinician Follow Up: Treatment Approaches Ilana B. Katz Sand, MD, New York, NY Satya Dash, MD, PhD, Toronto, ON, Canada

6:00 p.m.–6:15 p.m. ET » Abstract: Body Mass Index and The Brain in Pain: Influence of BMI Level on Migraine Patients Seen at a Large Tertiary Headache Center Gabriella O'Fallon, Seattle, WA 6:15 p.m.–6:30 p.m. ET » Abstract: Changes in Leptin, CCL16 and sTNFRII as a Distinctive Plasma Immune Profile in Patients with Fast Progressing ALS Vincent Picher-Martel, MD, Québec, QC, Canada 6:30 p.m.–7:00 p.m. ET » Panel Discussion Faculty

AAN.com/21AM

NEUROSCIENCE IN THE CLINIC SESSIONS

metabolic, immune, and reproductive—that influence susceptibility to neurological and neuropsychiatric disease. In this Neuroscience in Clinic Session, we will examine the neuroepidemiology of obesity, specifically the role of obesity as a risk factor for neurology diseases; neuropsychiatric and metabolic manifestations of obesity; and shared neural pathways in body weight regulation with neurological disease, as uncovered by genetics. Our invited scientists will review specific endocrine (including adipokines), neural, and other mechanisms of obesity and their relation to neurological diseases. Finally, we will discuss obesity treatments including dietary interventions (e.g., very low energy diets, intermittent fasting), pharmacotherapy (e.g., GLP-1 analogs, growth hormone treatment), and bariatric surgery. Outcomes that will be discussed include Alzheimer's Disease and Related Dementias (ADRD), cerebral small vessel disease, depression, schizophrenia, attention deficit hyperactivity disorder (ADHD), autism, multiple sclerosis, and Huntington's Disease.

NEUROSCIENCE IN THE CLINIC

Neuroscience in the Clinic: Emerging Neuroscience in Neurologic Complications of COVID-19

Monday, April 19

Directors:

CME

2:00 p.m.–4:00 p.m. ET

Kiran Thakur, MD, New York, NY Shibani Sharon Mukerji, MD, Boston, MA

Description: In this session, a mix of scientists and clinicians will engage in lively case discussion to

NEUROSCIENCE IN THE CLINIC SESSIONS

integrate scientific research with clinical application.

2:00 p.m.–2:05 p.m. ET » Introduction Kiran Thakur, MD, New York, NY 2:05 p.m.–2:20 p.m. ET » Big Picture Context Over Pandemics Tom Solomon, MD, Liverpool, United Kingdom 2:20 p.m.–2:35 p.m. ET » Unanswered Scientific Questions Avindra Nath, MD, MBBS, FAAN, Bethesda, MD 2:35 p.m.–2:50 p.m. ET » Neuropathology Faculty 2:50 p.m.–3:05 p.m. ET » Immunological Overview Faculty

24 2021 AAN Annual Meeting

3:05 p.m.–3:20 p.m. ET » Abstract: CSF of SARS-CoV-2 Patients with Neurological Syndromes Does Not Display Evidence of Strong Immune Response But Reveals Hints to Understand Neurologic Pathophysiology Raphael Bernard-Valnet, MD, PhD, Lausanne, Switzerland 3:20 p.m.–3:35 p.m. ET » COVID Impact on Acute Stroke Care Mitchell S. V. Elkind, MD, MS, FAAN, New York, NY 3:35 p.m.–3:50 p.m. ET » Abstract: Low-Field, Portable Magnetic Resonance Imaging at the Bedside to Assess Brain Injury in Patients with Severe COVID-19 Mercy Mazurek, New Haven, CT 3:35 p.m.–4:00 p.m. ET » Wrap Up and Final Questions Faculty

Neuroscience in the Clinic: CAR-T Cell Therapy: Neurologic Applications and Neurotoxicity

Tuesday, April 20 5:00 p.m.–7:00 p.m. ET

Directors:

CME

Holly E. Hinson, MD, MCR, FAAN, Portland, OR Antonio M. P. Omuro, MD, New Haven, CT

Description: Anti-cancer immunotherapy has come of age. While suspected for decades, it was not

5:00 p.m.–5:05 p.m. ET » Introduction Antonio M. P. Omuro, MD, New Haven, CT 5:05 p.m.–5:25 p.m. ET » Case Presentation Holly E. Hinson, MD, MCR, FAAN, Portland, OR 5:25 p.m.–5:55 p.m. ET » Basic Science Behind Cancer Immunotherapy and Clinical Implications Bianca Santomasso, MD, New York, NY 5:55 p.m.–6:00 p.m. ET » Break

6:00 p.m.–6:15 p.m. ET » Abstract: Advancing Antigen-Specific T cell Therapy for Progressive Multifocal Leukoencephalopathy Sasha Gupta, MD, San Francisco, CA 6:15 p.m.–6:30 p.m. ET » Abstract: Anakinara to Mitigate CAR T Cell Therapy Associated Toxicity Sudhakar Tummala, MD, Houston, TX 6:30 p.m.–7:00 p.m. ET » Wrap up of Case and Panel Discussion Faculty

Join Us for National Institutes of Health Day! Tuesday, April 20, 2021, 1:30 p.m.—6:00 p.m. ET Join our partners from the National Institutes of Health for updates on their programs, strategic focus, and funding priorities. There will be several talks with multiple opportunities for live Q&A. Learn more at AAN.com/2021Program. AAN.com/21AM

NEUROSCIENCE IN THE CLINIC SESSIONS

until recently that cancer cells have been proven to be immunogenic. And now treatments based on this concept have translated into treatments that improve survival in cancer patients. There are a growing number of FDA approved drugs that target the immune system as their anti-neoplastic mechanism of action. However, neurologic side effects are common with many of these new treatments. In this session, faculty will present a challenging case of neurotoxicity after CAR-T cell therapy. Faculty will review the basic science behind cancer immunotherapy and neurologic side effects of immunotherapy. Abstracts will be presented, and a panel discussion will follow.

NEUROSCIENCE IN THE CLINIC N5

Neuroscience in the Clinic: Melatonin and Disrupted Sleep in Neurologic Disorders

Wednesday, April 21

Directors:

CME

2:00 p.m.–4:00 p.m. ET

Aleksandar Videnovic, MD, MSc, FAAN, Boston, MA Temitayo Oyegbile, MD, PhD, Sacramento, CA

NEUROSCIENCE IN THE CLINIC SESSIONS

Description: Adults and children with neurologic disorders such as epilepsy, migraine, autism, Parkinson’s,

stroke, and concussion often experience significantly disrupted sleep. There is accumulating evidence suggesting that melatonin may play a role in this interaction between neurologic disorders and sleep disruption. This program will address what is known about the role of melatonin in brain activity, and how this may pertain to fluctuations in neurologic function and sleep abnormalities. The program will draw on examples from multiple sclerosis, Parkinson’s, autism, headache, epilepsy, cerebrovascular disease, and other neurologic conditions. The program will also emphasize potential approaches to modulating the effect of melatonin to optimize sleep and treatment of neurologic disorders.

2:00 p.m.–2:10 p.m. ET » General Overview: Specific Neurologic Disorders and Disrupted Sleep: Highlighting the Role of Melatonin Temitayo Oyegbile, MD, PhD, Sacramento, CA 2:10 p.m.–2:20 p.m. ET » Clinical Vignette: Sleep Disruption and Migraine Temitayo Oyegbile, MD, PhD, Sacramento, CA 2:20 p.m.–2:50 p.m. ET » Sleep, Clocks, and Melatonin in Neurologic Disorders Aleksandar Videnovic, MD, MSc, FAAN, Boston, MA 2:50 p.m.–3:05 p.m. ET » Melatonin-Modulating Strategies to Improve Sleep Temitayo Oyegbile, MD, PhD, Sacramento, CA

26 2021 AAN Annual Meeting

3:05 p.m.–3:15 p.m. ET » Clinical Vignette Wrap Up Faculty 3:15 p.m.–3:30 p.m. ET » Abstract: Development and Characterization of Light-Triggered Sleep-Deprivation Preclinical Migraine Model in Females and Males Skyler Kanegi, San Antonio, TX 3:30 p.m.–3:45 p.m. ET » Abstract: Timeline, Incidence, Frequency, and Survival of REM Sleep Behavior Disorder in Overt Alpha-Synucleinopathies Cole Stang, Rochester, MN 3:45 p.m.–4:00 p.m. ET » Panel Discussion Faculty

Neuroscience in the Clinic: Multimodal Tools for Cardiac Arrest Neuroprognostication

Wednesday, April 21

Directors:

CME

5:00 p.m.–7:00 p.m. ET

Holly E. Hinson, MD, MCR, FAAN, Portland, OR Martinson K. Arnan, MD, Kalamazoo, MI

Description: The science of prognosticating neurologic outcome following cardiac arrest in the era of

targeted temperature management has been fast-moving over the past few years. This session features case vignettes and expert clinical commentary on how best to utilize biomarkers, imaging, and emerging technologies when making outcome predictions. Top abstracts related to post-cardiac arrest care and prognostication will be presented, with opportunities for panel discussion.

5:00 p.m.–5:05 p.m. ET » Introduction Martinson K. Arnan, MD, Kalamazoo, MI 5:05 p.m.–5:15 p.m. ET » Case Presentation Sachin Agarwal, MD, MPH, New York, NY 5:15 p.m.–5:55 p.m. ET » Current Clinical Algorithms for Neurologists Approaching the Cardiac Arrest Patient Karen Hirsch, MD, Palo Alto, CA 6:20 p.m.–6:35 p.m. ET » Abstract: Dues Detailed EEG Pattern MEM: 21 Membership Ad—AM Bookletand Spectral Placed in AMAnalysis Booklet Can Prognosticate Good and Poor 6 x 4.75 +0.125 bleed, 4C Outcomes After Cardiac Arrest Neurologic Kurt Qing, MD, New York, NY

Global Community

6:35 p.m.–6:50 p.m. ET » Abstract: Prognostic Performance of Serum Neuron Specific Enolase (NSE) in Comatose Cardiac Arrest Survivors: A Multiple Thresholds Meta-analysis Merin John, League City, TX 5:55 p.m.–6:20 p.m. ET » Case Presentation: Follow Up Sachin Agarwal, MD, MPH, New York, NY 6:50 p.m.–7:00 p.m. ET » Summary of Discussion and Questions and Answers Faculty

Virtual Conferences

Online Learning

Networking

Scientific Research

Count on the AAN to provide top-quality education, events, networking, and other programs and opportunities—in new virtual formats that offer greater flexibility and easy access to your worldwide neurology community. Join or renew today!

AAN.COM/MEMBERSHIP

AAN.com/21AM

Laundry

Arms tired again

Sam’s 3rd Birthday Party

Canceled: weak legs

Ballet pick-up

COULDN’T DRIVEvision problems

Brunch with friends

Good day!

Big family dinner

Trouble chewing Patient Portrayal

DISCOVER WHY UNCONTROLLED gMG NEVER RESTS 50-75% of patients with generalized

myasthenia gravis (gMG) remain uncontrolled.1,2

For many patients, moderate-to-severe symptoms, along with the ongoing risk of exacerbations, can disrupt daily life.1,3

JOIN UCB AT THE 2021 AAN ANNUAL MEETING Participate in our UCB Industry Therapeutic Update Tuesday, April 20th 9 – 10 am ET

Explore uncontrolled gMG at gMGFacts.com REFERENCES: 1. Cutter G, Xin H, Aban I, et al. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment. Muscle Nerve. 2019;60(6):707-715. doi:10.1002/mus.26695 2. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141149. doi:10.1002/mus.20950 3. Xin H, Harris LA, Aban IB, Cutter G. Examining the impact of refractory myasthenia gravis on healthcare resource utilization in the United States: analysis of a Myasthenia Gravis Foundation of America Patient Registry sample. J Clin Neurol. 2019;15(3):376-385. doi:10.3988/ jcn.2019.15.3.376 The Industry Therapeutic Update is not a part of the AAN official programming and there is not CME offered for attendance. ©2021 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-S-DA-2000045. Date of Preparation: February 2021

Health Care Equity Symposium Quality Health Care for All

Monday, April 19, 2021, 1:00 p.m.–3:00 p.m. ET In today’s world, the reality is that access to quality health care varies greatly depending on race, gender, socioeconomic status, and sexual identity. Join us at the Health Care Equity Symposium as we explore ways we can eliminate the disparity gap. This symposium will include the Cheryl A. Jay Keynote Lecture, presented by Joseph R. Betancourt, MD, MPH, followed by a panel discussion and live Q&A session, featuring: Richard T. Benson, MD, PhD ■ National Institute of Neurological Disorders and Stroke NIH Office of Global Health and Health Disparities

Nicte I. Mejia, MD, MPH, FAAN ■ Harvard Medical School and Massachusetts

Nicole Rosendale, MD ■ University of California, San Francisco Jeffrey C. McClean II, MD, FAAN, Lt Col ■ USAF, MC BAMC Department Of Medicine

General Hospital

Learn more: AAN.com/21AM

Cheryl A. Jay Keynote Lecture Dr. Cheryl A. Jay (1960 – 2019) was a gifted clinical neurologist who was passionate about social justice in health care and serving the underprivileged.

JOSEPH R. BETANCOURT, MD, MPH Expert in health policy, health care disparities, diversity, and cross-cultural medicine. ■ Vice President, Chief Equity and Inclusion Officer, Massachusetts General Hospital ■ Founder, Senior Advisor and Faculty, The Disparities Solutions Center ■ Faculty, The Mongan Institute ■ Associate Professor of Medicine, Harvard Medical School

INVITED SCIENCE Invited Science: Neuromuscular Saturday, April 17

CME

4:00 p.m.–5:00 p.m. ET

This session will highlight cutting-edge science of hot topics in neuromuscular disease in partnership with the Peripheral Nerve Society.

Invited Science: Movement Disorders Monday, April 19

CME

4:00 p.m.–5:00 p.m. ET

This session will highlight cutting-edge science and hot topics in movement disorders, in partnership with the International Parkinson and Movement Disorder Society.

Invited Science: Child Neurology Wednesday, April 21

CME

2:00 p.m.–3:00 p.m. ET

This session will highlight cutting-edge science and hot topics in child neurology, in partnership with the Child Neurology Society.

YOU DON’T WANT TO MISS THIS.

Sanjay Gupta, MD Public Leadership in Neurology Award

April 21, 2021 • 8-9 p.m. ET Join us virtually for an inspiring night honoring how far we’ve come in the fight against brain disease. This virtual experience will feature celebrity guests, a musical performance, a craft cocktail demo, inspiring stories from those impacted by brain disease, and more!

Cindy McCain Commitment to Cures Award

Khloé Kardashian Ambassador Award

Get your ticket when you register for the AAN Annual Meeting or visit AmericanBrainFoundation.org/C2C2021

30 2021 AAN Annual Meeting

Jim Cramer Master of Ceremonies

Credible scientific information for healthcare providers, payers, and policymakers. Each quarter we’ll extract the most critical cannabinoid-related news, legislation and policies that you need to know.

SCAN HERE to sign up

SCIENTIFIC SESSIONS Each scientific session presents a group of abstracts covering a similar topic. You'll hear a total of five abstracts presented during each session with interactive audience Q&A after the second and fifth abstracts are presented.

Saturday, April 17, 2021 S1 Epilepsy and Clinical

CME

Neurophysiology (EEG) 1

2:00 p.m. ET

S1.001

2:08 p.m. ET

S1.002

SCIENTIFIC SESSIONS

Fetal Antiseizure Medication Effects on Neuropsychological Outcomes at Age 3 Years in the MONEAD Study—Kimford J. Meador, Morris Cohen, David W. Loring, Carrie Brown, Chelsea Robalino, Page B. Pennell Efficacy of Cenobamate for Uncontrolled Focal Seizures: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study—Michael R. Sperling, Bassel W. Abou-Khalil, Sami M. Aboumatar, Perminder JS Bhatia, Victor Biton, Pavel Klein, Gregory L. Krauss, David G. Vossler, Robert T. Wechsler, Louis Ferrari, Marc Kamin, Mindy Grall, William E. Rosenfeld

S2 Advances in MS Imaging 2:00 p.m. ET

S2.001

2:08 p.m. ET

S2.002

CME

Neurite Density Explains Cortical T1-/T2Weighted Ratio in Multiple Sclerosis—Paolo Preziosa, Piet Bouman, Svenja Kiljan, Martijn D Steenwijk, Alessandro Meani, Petra Pouwels, Maria Assunta Rocca, Massimo Filippi, Jeroen JG Geurts, Laura Jonkman

Questions and Answers

The Importance of Neuroradiology Input at a Neuroinflammatory Multidisciplinary Team (MDT) Meeting: Influencing and Optimising the Management of Patients with Multiple Sclerosis—Stephen Ramsay, Robert Spence, Rebecca Robinson, Niamh Turley, Debarata Bhattacharya, Adam Nelson, Peter Flynn, Aidan G. Droogan, Stella Elaine Hughes, Fiona Kennedy, Gavin V. McDonnell

2:24 p.m. ET

2:16 p.m. ET

S1.003

Cenobamate Trough Plasma Concentrations in Patients With Uncontrolled Focal Seizures Achieving 50% and 100% Seizure Reduction in Two Randomized Clinical Studies—Stephen Greene, Marc Kamin

2:32 p.m. ET

S1.004

2:40 p.m. ET

S1.005

HMGB1 as a Therapeutic Target of Focal Cortical Dysplasia—Yang Zheng, Yi Wang, MeiPing Ding, Zhong Chen Efficacy, Safety, and Tolerability of Soticlestat (TAK-935/OV935) as Adjunctive Therapy in Pediatric Patients with Dravet Syndrome and Lennox-Gastaut Syndrome (ELEKTRA) —Cecil D. Hahn, Yuwu Jiang, Vicente Villanueva, Marta Zolnowska, Dimitrios Arkilo, Peter B. Forgacs, Mahnaz Asgharnejad, Ying Yan, Dennis J. Dlugos

2:48 p.m. ET

Questions and Answers

2:24 p.m. ET

S2.003

2:32 p.m. ET

S2.004

2:40 p.m. ET

S2.005

Relevance of NODDI to Characterise in Vivo the Microstructural Abnormalities of Multiple Sclerosis Cortex and Cortical Lesions: A 3T Study—Paolo Preziosa, Elisabetta Pagani, Raffaello Bonacchi, Laura Cacciaguerra, Massimo Filippi, Maria Assunta Rocca Vascular Disease Risk Factors in Multiple Sclerosis (MS) is Associated with Brain Adenosine Triphosphate Abnormalities: Dysmetabolism May Drive MS Disease Progression—Vijayshree Yadav, Michael Lane, Allison Fryman, Manoj K. Sammi Choroid Plexus Enlargement Characterizes Inflammatory Multiple Sclerosis—Vito Antonio Gerardo Ricigliano, Emanuele Morena, Annalisa Colombi, Matteo Tonietto, Mariem Hamzaoui, Emilie Poirion, Michel Bottlaender, Celine Louapre, Benedetta Bodini, Bruno Stankoff

2:48 p.m. ET

Questions and Answers

32 2021 AAN Annual Meeting

S3 Movement Disorders 1 2:00 p.m. ET

CME

S3.001

Understanding the Natural History of SCA2, SCA3, and SCA10 Through Clinical Scales— Marise Zonta, Helio Afonso Ghizoni Teive, Carlos Henrique Ferreira Camargo, Alex Meira, Francisco Diego Negr Neto, Fernando Spina Tensini, Tetsuo Ashizawa, Renato Puppi Munhoz

2:08 p.m. ET

S3.002

2:16 p.m. ET

Questions and Answers

2:24 p.m. ET

S3.003

The Role of the Cerebellum in Tremor-dominant Cervical Dystonia—Abhimanyu Mahajan, Lyndsey Schroder, Aleksander Rekhtman, Alok Dwivedi, Lily Wang, Alberto J. Espay

2:32 p.m. ET

S3.004

PD GENEration: Feasibility and Impact of Providing In-Person Versus Remote Genetic Testing and Counseling for People with Parkinson’s Disease—Jennifer Verbrugge, Lola Shukla, Jeanine Schulze, Tae-Hwi Schwantes-An, James Beck, Anna Naito, Anne Hall, Karen S. Marder, Martha A. Nance, Michael Schwarzschild, Tanya Simuni, Hector M. Gonzalez, Roy Alcalay

2:40 p.m. ET

S3.005

Efficacy and Safety of SEP-363856, a Non–D2Receptor Binding Drug With Antipsychotic Activity, in Patients With Parkinson’s Disease Psychosis—Stuart H. Isaacson, Mark A. Goldstein, Rajesh Pahwa, Carlos Singer, Kevin J. Klos, Ian Zhang, David Crandall, Bradford Navia

2:48 p.m. ET

Questions and Answers

CME

Developmental Neurology

4:00 p.m. ET

S4.001

4:08 p.m. ET

S4.002

Onasemnogene Abeparvovec Gene Therapy in Presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT Study Update in Children with 3 Copies of SMN2—Kevin Strauss, Francesco Muntoni, Michelle A. Farrar, Kyoko Saito, Jerry R. Mendell, Laurent Servais, Hugh John McMillan, Kathryn J. Swoboda, Jennifer M. Kwon, Craig M. Zaidman, Claudia A. Chiriboga, Susan T. Iannaccone, Jena M. Krueger, Julie Anne Parsons, Perry Shieh, Sarah Kavanagh, Deepa Chand, Sitra TauscherWisniewski, Thomas Macek ASPIRO Gene Therapy Trial In X-Linked Myotubular Myopathy (XLMTM): Update on Preliminary Efficacy and Safety Findings—Perry Shieh, Nancy L. Kuntz, James Dowling, Wolfgang Mueller-Felber, Astrid Blaschek, Carsten G. Bonnemann, A. Reghan Foley, Dimah N. Saade, Andreea Mihaela Seferian, Laurent Servais, Michael W Lawlor, Mojtaba Noursalehi, Suyash Prasad, Salvador Rico, Weston Miller

4:16 p.m. ET

Questions and Answers

4:24 p.m. ET

S4.003

4:32 p.m. ET

S4.004

4:40 p.m. ET

S4.005

The RIKEE database: Genotype-Phenotype Patterns in KCNQ Channel Related Disease, Based on 784 Individuals and Pedigrees— Edward C. Cooper, John J. Millichap, Tammy Tsuchida, Maurizio Taglialatela, Sarah Weckhuysen Improving Triaging of EEG Referrals for Rule out Infantile Spasms (ITERIS) —Djurdja Djordjevic, Jennifer Tracey, Cristina Y. Go Long-Term Follow-Up (LTFU) of Onasemnogene Abeparvovec Gene Therapy in Spinal Muscular Atrophy (SMA) —Jerry R. Mendell, Richard S. Finkel, Eugenio Mercuri, Kevin Strauss, John W. Day, Aaron Kleyn, Deepa Chand, Sitra Tauscher-Wisniewski, Matthew N. Meriggioli

4:48 p.m. ET

Questions and Answers

AAN.com/21AM

SCIENTIFIC SESSIONS

Analysis of 96-Week, Long-Term Open Label Extension Phase of Study BHV4157-201: A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Troriluzole in Adult Subjects with Spinocerebellar Ataxia—Melissa Beiner, Victoria Wirtz, Gilbert J. L'Italien, Laura Ruggiero, Robert Berman, Vlad Coric

S4 Child Neurology and

SCIENTIFIC SESSIONS Saturday, April 17, 2021 S5 Headache 1 4:00 p.m. ET

CME

S5.001

Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine— Messoud Ashina, Stewart J. Tepper, Uwe Reuter, Andrew M. Blumenfeld, Susan Hutchinson, Jing Xia, Rosa Miceli, Lawrence Severt, Michelle Finnegan, Joel M. Trugman

SCIENTIFIC SESSIONS

4:08 p.m. ET

S5.002

Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study—Susan Hutchinson, Jack D. Schim, Richard B. Lipton, Robert Croop, Christopher Jensen, Alexandra Thiry, Elyse Stock, Charlie Conway, Meghan Lovegren, Vlad Coric, Michael Hanna

4:16 p.m. ET

Questions and Answers

4:24 p.m. ET

S5.003

Intranasal Zavegepant is Effective and Well Tolerated for the Acute Treatment of Migraine: A Phase 2/3 Dose-Ranging Clinical Trial—Robert Croop, Jennifer Madonia, Charlie Conway, Alexandra Thiry, Micaela Forshaw, Abigail Murphy, Christopher Jensen, Gene Dubowchik, Vlad Coric, Richard B. Lipton

4:32 p.m. ET

S5.004

Ubrogepant Was Safe and Well Tolerated in the Acute Treatment of Perimenstrual Migraine— Jelena M. Pavlovic, Jessica Ailani, Susan Hutchinson, Jeff Lai, Brett Dabruzzo, Sung Y. Yu, Joel M. Trugman, Anne MacGregor

S6 Cerebrovascular Disease and

CME

Interventional Neurology: Acute Stroke Treatment

4:00 p.m. ET

S6.001

4:08 p.m. ET

S6.002

Prediction of Infarct Volume at the 24 Hours after Late Window Presentation with Perfusion Imaging in Patients with Anterior Circulation Large Vessel Occlusion—Shashank Agarwal, Eytan Raz, Seena Dehkharghani, Soren Christensen, Maarten G. Lansberg, Shadi Yaghi, Adam De Havenon Current Utilization of Endovascular Mechanical Thrombectomy in the Treatment of Acute Ischemic Stroke in the US—Isobel MacKenzie, Dimitri Sigounas

4:16 p.m. ET

Questions and Answers

4:24 p.m. ET

S6.003

4:32 p.m. ET

S6.004

4:40 p.m. ET

S6.005

Blood Pressure Reductions in the Hyperacute Phase of Large Vessel Occlusion Ischemic Stroke Are Associated With Infarct Progression And Poor Functional Outcome—Krithika Umesh Peshwe, Cindy Khanh Phuong Nguyen, Sreeja Kodali, Jessica Kobsa, Ayush Prasad, Alexandria Soto, Charles R. Wira, Charles Matouk, Kevin N. Sheth, Nils Petersen Reduction of Door to Groin Puncture Time for Mechanical Thrombectomy After Implementation of Ventura ELVO Score (VES) — Syed A. Quadri, Sajid Suriya, Mudassir Farooqui, Aqsa Baig, Muhammad Taqi

Real World Efficacy, Tolerability, and Safety of Ubrogepant—Chia-Chun Chiang, Karissa Arca, Rachel Dunn, Marlene Girardo, Jaxon Quillen, David W. Dodick, Amaal J. Starling

Readmission In Acute Ischemic Stroke Patients Undergoing Endovascular Treatment—Saqib A. Chaudhry, Ibrahim Laleka, Hussan Gill, Mohammad Rauf A. Chaudhry, Ameer Hassan, Haseeb Abdul Rahman, Zelalem Bahiru, Iqra N Akhtar, Sairah Bashir, Jing Wang, Yun Fang, Laith Altaweel, Adnan I. Qureshi

4:48 p.m. ET

4:40 p.m. ET

S5.005

Questions and Answers

34 2021 AAN Annual Meeting

Questions and Answers

Sunday, April 18, 2021 S7 Autoimmune and Paraneoplastic

CME

Neurologic Disorders: Diagnosis, Epidemiology, and Pathophysiology

2:00 p.m. ET

S7.001

Population-Based Epidemiology Study of Paraneoplastic Neurological Syndromes— Shailee Samir Shah, Eoin P. Flanagan, Pritikanta Paul, Carin Smith, Sandra Bryant, Andrew McKeon, Sean J. Pittock, Divyanshu Dubey

S8 Neuromodulation in Movement

CME

Disorders

2:00 p.m. ET

S8.001

2:08 p.m. ET

S8.002

Electrophysiological Evidence for DBS Influencing Network Versus Individual Neuron Activity in the Subthalamic Nucleus—Ashley C. Guest, Dakota Graham, Margaret Lambert, Holly A. Shill, Francisco Ponce, Bradley Greger

2:16 p.m. ET

2:08 p.m. ET

S7.002

Questions and Answers

2:24 p.m. ET

S8.003

2:32 p.m. ET

S8.004

2:40 p.m. ET

S8.005

S7.003

Anti-Metabotropic Glutamate Receptor (mGluR)1 Encephalitis: Identification Of Prognostic Factors And Study Of Antibody Effects—Marianna Spatola, Mar Petit-Pedrol, Estibaliz Maudes, Mateus Mistieri Simabukuro, Sergio Muniz-Castrillo, Anne-Laurie Pinto, KlausPeter Wandinger, Juliane Spiegler, Peter Schramm, Livia Almeida Dutra Antonio, Raffaele Iorio, Cornelia Kornblum, Romana Hoeftberger, Frank Leypoldt, Maarten Jan Titulaer, Peter Sillevis Smitt, Jerome Honnorat, Myrna R. Rosenfeld, Francesc R. Graus, Josep O. Dalmau

2:32 p.m. ET

S7.004

Seizure-related 6 Homolog like 2 (SEZ6L2) Aautoimmunity: Neurologic Syndrome and Antibody Effects—Mar Guasp, Jon Landa, Mar Petit-Pedrol, Eugenia Martinez-Hernandez, Jesus Planaguma, Albert Saiz, Raquel Ruiz-Garcia, Lorena Garcia, Jan Verschuuren, Rachel J. Saunders-Pullman, Liliana A. Ramirez-Gomez, Michael D. Geschwind, Josep O. Dalmau, Lidia Sabater, Francesc R. Graus

2:40 p.m. ET

S7.005

The Positive Predictive Value of Aquaporin-4 Antibody Live Cell-based Assay in a Tertiary Referral Center—Mayra Montalvo Perero, Sean J. Pittock, Elia Sechi, James Fryer, Andrew McKeon, John R. Mills, John Chen, Eoin P. Flanagan

10-Year Clinical Outcomes of Subthalamic Nucleus versus Pallidal Deep Brain Stimulation for Parkinson’s Disease: VA/NINDS CSP #468F—Jill L. Ostrem, Ping Luo, Frances Weaver, Kenneth Follett, Nicholas B. Galifianakis, Eugene C. Lai, Jeff M. Bronstein, John E. Duda, Kathryn Holloway, Aliya Sarwar, Matthew A. Brodsky, Kathryn Anne Chung, Meredith Spindler, Domenic Reda, Johannes Rothlind, Amanda Snodgrass, William J. Marks Long-Term Evaluation of Deep Brain Stimulation for Treatment of Parkinson's Disease Using a Multiple-Source, Constant-Current Rechargeable System: 4-year Follow-Up of a Prospective, Double-Blind RCT—Jerrold L. Vitek, Roshini Jain, Lilly Chen, INTREPID Study Group, Philip Starr North American Survey on the Effects of the COVID-19 Pandemic Shutdown on DBS Care—Mustafa S. Siddiqui, Sol T. De Jesus, Harini Sarva, James McInerney, Fedor Panov, Michele K. York, Jason Schwalb, Zoltan Mari, Benjamin L. Walter, Joshua M. Rosenow, Neepa J. Patel, John M. Bertoni, Lin Zhang, Joohi Jimenez Shahed

2:48 p.m. ET

Questions and Answers

2:48 p.m. ET

Questions and Answers

AAN.com/21AM

SCIENTIFIC SESSIONS

Thymoma-associated Neuronal Surface Antibodies and Clinical Manifestations—Mar Guasp, Eugenia Martinez-Hernandez, Jon Landa, Lidia Sabater, Albert Saiz, Francesc R. Graus, Josep O. Dalmau

Identifying a Gait Circuit from Focal Stroke Lesions and Deep Brain Stimulation Connectivity in Parkinson’s Disease—Lan Luo, Frederic Schaper, Sandrine Jabbour, Joey Hsu, Louis Soussand, Shan Siddiqi, Andreas Horn, Martin Reich, Jens Volkmann, Andrea Kuehn, Maurizio Corbetta, Michael D. Fox

SCIENTIFIC SESSIONS Sunday, April 18, 2021

S9 Sleep: Highlight Presentations

CME

on RBD

2:00 p.m. ET

S9.001

2:08 p.m. ET

S9.002

Effects of Solriamfetol on Driving Performance in Participants With Narcolepsy—Frederick Vinckenbosch, Gerrit Jan Lammers, S Overeem, Dan Chen, Grace Wang, LP Carter, Kefei Zhou, Jan Ramaekers, Annemiek Vermeeren

SCIENTIFIC SESSIONS

Quality of Life in a Phase 3, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of Lower-Sodium Oxybate in Adults With Narcolepsy With Cataplexy—Nancy R. FoldvarySchaefer, Michael J. Thorpy, Yves Dauvilliers, Asim Roy, Lihua Tang, Roman Skowronski, Karel Sonka, Richard K. Bogan

2:16 p.m. ET

Questions and Answers

2:24 p.m. ET

S9.003

Frequency and Predictors of Obstructive Sleep Apnea in a Cognitively Impaired Clinic Population—David Robert Colelli, Sandra E. Black, Mario Masellis, Benjamin Lam, Andrew Lim, Mark Boulos

2:32 p.m. ET

S9.004

Cutaneous Alpha-Synuclein is Correlated with Autonomic Impairment in Isolated REM Sleep Behavior Disorder—Mitchell G. Miglis, Jennifer Zitser-Koren, Sharika Rajan, Emmanuel H. During, Logan D. Schneider, Safwan S. Jaradeh, Roy L. Freeman, Christopher H. Gibbons

2:40 p.m. ET

S9.005

Patient Preferences for Prognostic Counseling in Idiopathic/Isolated REM Sleep Behavior Disorder—Thomas Gossard, Luke Teigen, Paul Timm, John Craig Feemster, Stuart McCarter, Erik Kent St. Louis

2:48 p.m. ET

Questions and Answers

36 2021 AAN Annual Meeting

S10 Epilepsy and Clinical

CME

Neurophysiology (EEG) 2

4:00 p.m. ET

S10.001

4:08 p.m. ET

S10.002

Modulation of Resting State Networks by Antiseizure Medications in Patients With Idiopathic Generalized Epilepsy—Juanita Espinosa, Karen Alves, Luiz Eduardo Betting Functional Connectivity for Disease Classification in Epilepsy: A Machine Learning Approach—Taha Gholipour, Xiaozhen You, Steven Stufflebeam, William D. Gaillard

4:16 p.m. ET

Questions and Answers

4:24 p.m. ET

S10.003

4:32 p.m. ET

S10.004

4:40 p.m. ET

S10.005

Assessment of the Validity of the 2HELPS2B Score for Inpatient Seizure Risk Prediction— Aaron F. Struck, Mohammad Tabaeizadeh Fesharaki, Christa Brittany Swisher, Christian Hernandez, Safa Kaleem, Hiba Arif Haider, Lawrence J. Hirsch, Eric Rosenthal, Sahar Fatima Zafar, M. Brandon Westover Convulsive Status Epilepticus: Who Dies and Why—Jessica Bloomfield, Fawaz Al-Mufti A Unique Population Based Epilepsy Network in Ontario Enhances Epilepsy Care and the Availability of Epilepsy Surgery—O. Carter Snead, Elizabeth Donner, Sharon E. Whiting, Tadeu Fantaneanu, Lysa Boisse Lomax, Esther Bui, Danielle M. Andrade, Taufik Valiante, Anastasia Vogt, Kirk Nylen, Rajesh RamachandranNair, Michelle Shapiro, James Rutka, Andrea Andrade, Ayman Emam H. Hassan, Jorge G. Burneo

4:48 p.m. ET

Questions and Answers

S11 MS Immunology and Basic

CME

Science

4:00 p.m. ET

S11.001

Plasma Neurofilament Light Chain and Glial Fibrillary Acidic Protein Levels Are Prognostic of Disability Worsening: A Biosignature That Helps Differentiating Active From Non-active SPMS—Jens Kuhle, Aleksandra Maleska Maceski, Rolf Meinert, Inga Ludwig, Thomas Hach, Ludwig Kappos, David Leppert, Harald Kropshofer

4:08 p.m. ET

S11.002

4:16 p.m. ET

Questions and Answers

4:24 p.m. ET

S11.003

Specific Blockade of Bone Morphogenetic Protein-2/4 induces Oligodendrogenesis and Remyelination in Demyelinating Disorders— Karin Fainberg-Mausner, Moshe Benhamou, Maya Golan, Nadav Bleich Kimelman, Uri Danon, Ehud Marom, Arnon Karni

4:32 p.m. ET

S11.004

Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: MAGNIFY-MS Study—Heinz Wiendl, Klaus Schmierer, Suzanne J. Hodgkinson, Tobias Derfuss, Andrew Chan, Finn Sellebjerg, Anat Achiron, Xavier Montalban, Alexandre Prat, Nicola De Stefano, Frederik Barkhof, Letizia M. Leocani, Patrick Vermersch, Anita Chudecka, Sanjeev Roy, Ursula Boschert

4:40 p.m. ET

S11.005

ACT-1004-1239, a First-in-class CXCR7 Antagonist with both Immunomodulatory and pPro-myelinating Effects, for the Treatment of Inflammatory Demyelinating Diseases—Laetitia Pouzol, Melanie Tunis, Anna Sassi, Julia Marrie, Enrico Vezzali, Herve Farine, Ulrich Mentzel, Marianne Martinic

4:48 p.m. ET

CME

Studies of Neuromuscular Diseases

4:00 p.m. ET

S12.001

4:08 p.m. ET

S12.002

Long-term Remission with Rituximab in Refractory Generalized Myasthenia Gravis— Juan Ignacio Castiglione, Fabio Adrian Barroso, Patricio Brand, Andrea Lautre, Alejandro Kohler The Canadian Neuromuscular Disease Registry: A National Spinal Muscular Atrophy (SMA) Registry for Real World Evidence—Maryam Oskoui, Victoria Hodgkinson, Bernard Brais, Craig Gordon Campbell, Joshua Lounsberry, Alex MacKenzie, Hugh John McMillan, Jiri Vajsar, Lawrence Korngut

4:16 p.m. ET

Questions and Answers

4:24 p.m. ET

S12.003

4:32 p.m. ET

S12.004

4:40 p.m. ET

S12.005

Non-dystrophic Myotonia: 2 Year Outcomes of Objective and Patient Reported Outcomes— Timothy R. Fullam, Swathy Chandrashekhar, Constantine Farmakidis, Duaa Jabari, Omar Jawdat, Mamatha Pasnoor, Mazen M. Dimachkie, Jeffrey Statland, CINCH Consortium SORD Neuropathy: Gene Identification and Proposal for a Follow Up Multi-Centre Natural History Study—Andrea Cortese, Maike Dohrn, Yi Zhu, Adriana Rebelo, Jingyu Wang, Jingyu Wang, Shawna Feely, Valerie Cassucio, Michaela AuerGrumbach, Sherifa Ahmed Hamed, Ruxu Zhang, Fiore Manganelli, Franco Taroni, Davide Pareyson, Henry Houlden, David N. Herrmann, Mary Reilly, Michael E. Shy, Asian Oceanic Inheri Consortium, Katie Stephens, Stephan Zuchner Description of Clinical Symptoms of a Large International Cohort of Patients with Valosincontaining-protein Related Disease—Marta Caballero-Avila, Chiseko Ikenaga, Chiara MariniBettolo, Michela Guglieri, Volker Straub, Rocio Nur Villar Quiles, Sarah Souvannanorath, Pascal Lafort, Tanya Stojkovic, Conrad Weihl, Jordi Diaz-Manera

4:48 p.m. ET

Questions and Answers

AAN.com/21AM

SCIENTIFIC SESSIONS

A Genome-Wide Association Study Highlights a Possible Involvement of Mast Cells and Neutrophils in Disease Activity in Multiple Sclerosis—Antonino Giordano, Melissa Sorosina, Ferdinando Clarelli, Laura Ferre, Silvia Santoro, Elisabetta Mascia, Miryam Cannizzaro, Massimo Filippi, Federica Esposito

S12 Interventional/Observational

SCIENTIFIC SESSIONS Monday, April 19, 2021

S13 Advances in General Neurology 2:00 p.m. ET

CME

S13.001

HELIOS-A: 9-month Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy—David D. Adams, Ivajlo Tournev, Mark Taylor, Teresa Coelho, Violaine PlanteBordeneuve, John L. Berk, Alejandra Gonzalez-Duarte, Julian D. Gillmore, Soon Chai Low, Yoshiki Sekijima, Laura Piera Obici, Rick Blakesley, Seth Arum, Rebecca Shilling, John Vest, Michael J. Polydefkis

2:08 p.m. ET

S13.002

SCIENTIFIC SESSIONS

A Computational Model of the Mutations of Cu-Zn Superoxide Dismutase 1 and Mechanisms for Protein Misfolding in Amyotrophic Lateral Sclerosis with Theoretical Nuclear Physics Methods—Joao Marcos Brandet

S14 Behavioral and Cognitive

CME

Neurology

2:00 p.m. ET

S14.001

2:08 p.m. ET

S14.002

Cortical Microstructure in Primary Progressive Aphasia: A Multicenter Study—Ignacio IllanGala, Victor Montal, Sergi Borrego Ecija, Neus Falgas Martinez, Maria Luisa Mandelli, Ariane E. Welch, Jordi Pegueroles, Daniel Alcolea Rodriguez, Mara Belan Sanchez Saudinos, Jordi Clarimon, Nuria Bargallo, Sofia Gonzalez-Ortiz, Albert Llado, Rafael G. Blesa, Howard J. Rosen, Bruce L. Miller, Maria Gorno Tempini, Raquel Sanchez-Valle, Alberto Lleo, Juan Fortea

Questions and Answers

Shorter Survival in Logopenic Progressive Crossed Aphasia in Dextrals—Marina Buciuc, Joseph Duffy, Mary M. Machulda, Jonathan GraffRadford, Nha Trang Thu Pham, Peter Martin, Matthew Senjem, Clifford R. Jack, Dennis W. Dickson, Val John Lowe, Jennifer Louise Whitwell, Keith A. Josephs

2:24 p.m. ET

2:16 p.m. ET

S13.003

Characterization of the Associations Between Pre-diabetes and Diabetes with Occurrence of Stroke by its Types, Subtypes, and Outcomes among West Africans—Mayowa Owolabi, Fred Sarfo, Kolawole W. Wahab, Albert K. Akpalu, Reginald Obiako, Edward Komolafe, Lukman Femi Owolabi, Godwin Osawaru Osaigbovo, Onoja Matthew Akpa, Joshua O. Akinyemi, Rufus O. Akinyemi, Bruce I. Ovbiagele

2:32 p.m. ET

S13.004

Cortical Oligodendrocyte Gene Networks Regulated by miR-142-3p are Associated with Tauopathy in Mice and Humans—Brent L. Fogel, Kathie Ngo, Cidi Chen, Carmela Abraham, Mohsen Ghanbari, Mohammad Ikram, Steven Kushner, Riki Kawaguchi, Giovanni Coppola, Kerstin Goth, Saverio Bellusci, Israel Hernandez, Kenneth S. Kosik, Jason D. Hinman

2:40 p.m. ET

S13.005

Plasma Phosphorylated Neurofilament Heavy Chain (pNF-H) Level is Associated with Future Motor Function in Nusinersen-treated Individuals with Later-onset Spinal Muscular Atrophy (SMA) —Michelle A. Farrar, Francesco Muntoni, Charlotte J. Sumner, Thomas O. Crawford, Richard S. Finkel, Eugenio Mercuri, Xiaotong Jiang, Jihee Sohn, Marco Petrillo, Steve Garafalo, Wildon Farwell

2:48 p.m. ET

Questions and Answers

38 2021 AAN Annual Meeting

Questions and Answers

2:24 p.m. ET

S14.003

2:32 p.m. ET

S14.004

2:40 p.m. ET

S14.005

A Highly Efficient Method for Single-Cell Electroporation in Mouse Organotypic Hippocampal Slice Culture—Amy Cheung, Kensuke Futai Lateralization of Motor Damage Influences the Features of Cognitive Impairment in ALS— Adriano Chio, Laura Peotta, Barbara Iazzolino, Rosario Vasta, Francesca Palumbo, Maria Claudia Torrieri, Luca Solero, Cristina Moglia, Antonio Canosa, Marco Pagani, Umberto Manera A Different Cognitive and Behavioral Profile in ALS Patients With or Without C9 or F72 Expansion—Cristina Moglia, Barbara Iazzolino, Laura Peotta, Jean Pierre Zucchetti, Antonio Canosa, Francesca Palumbo, Umberto Manera, Maura Brunetti, Andrea Calvo, Adriano Chio

2:48 p.m. ET

Questions and Answers

S15 Headache 2 2:00 p.m. ET

S15.001

2:08 p.m. ET

S15.002

CME

Impact of Abuse on Migraine Symptoms and Comorbidity: Results from the American Registry for Migraine Research (ARMR) — Meesha Trivedi, Gina Dumkrieger, Catherine Daniela Chong, David W. Dodick, Todd J. Schwedt Understanding the Impact of Sex and Race on the Migraine Patient’s Journey in the United States: Analyses From an Annual CrossSectional Patient Chart Audit—Robert Cowan, Meg Stabb, Nicholas Robinson, Virginia Schobel

2:16 p.m. ET

Questions and Answers

S15.003

Mindfulness Meditation vs. Headache Education for Migraine: A Randomized Clinical Trial— Rebecca E. Wells, Nathaniel O'Connell, Charles Pierce, Paige Estave, Donald B. Penzien, Elizabeth Loder, Fadel Zeidan, Timothy Houle

2:32 p.m. ET

S15.004

Assessing Barriers to Care in Episodic and Chronic Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study—Dawn C. Buse, Cynthia Emilie Armand, Larry Charleston, Michael L. Reed, Kristina Fanning, Aubrey Manack Adams, Richard B. Lipton

2:40 p.m. ET

S15.005

Calcitonin Gene-Related Peptide Inhibitor Use for Migraine Associated with Exacerbation of Raynaud Phenomenon—Ilana Breen, Caitlin Brumfiel, Meera Simmi Patel, Juliana VanderPluym, Aaron Griffing, Mark Pittelkow, Aaron Mangold

2:48 p.m. ET

Questions and Answers

CME

4:00 p.m. ET

S16.001

4:08 p.m. ET

S16.002

Prognostic Importance of the Extent of Resection in IDH-wild Type Grade II Astrocytomas According to EGFR Amplification and pTERT Mutation—Francesco Bruno, Valeria Interno, Alessia Pellerino, Antonio Silvani, Tamara Ius, Lorenzo Bello, Giuseppe Lombardi, Andrea Pace, Giuseppe Minniti, Riccardo Soffietti, Roberta Ruda Clinical and Survival Characteristics of Gliosarcoma Patients—Ahmad Amer, SWAPNIL KHOSE, Hamza Alhasan, Halyna Pokhylevych, Gregory Fuller, Noah Chasen, John F. De Groot, Jason Johnson

4:16 p.m. ET

Questions and Answers

4:24 p.m. ET

S16.003

4:32 p.m. ET

S16.004

4:40 p.m. ET

S16.005

Adult Pilocytic Astrocytoma in the Molecular Era: Surveying the Prevalence of MAPK Pathway Dysfunction and Overlap with Aggressive Features—Timothy Gregory, Lyndon Chumbley, Brett J. Theeler Long-term Follow-up of Schwannoma Growth Behavior in Adult Neurofibromatosis Type 2 and Schwannomatosis Patients Using Whole-body MRI—Ina Ly, Raquel D. Thalheimer, Wenli Cai, Miriam Bredella, Alona Muzikansky, Vanessa Merker, Hamilton Herr, Jennifer Da, Gordon Harris, Scott R. Plotkin, Justin T. Jordan Clinical and Molecular Features of a Prospectively-Sequenced Cohort of Glioblastoma Patients with Inherited Disorders in Mismatch Repair—Kevin Elmore, Zsofia Stadler, Anna Piotrowski, Lauren Rhea Schaff, Igor T. Gavrilovic, Jacqueline Stone, Ira Dunkel, Viviane Tabar, Ingo K. Mellinghoff, Tejus Bale, Andrew L. Lin

4:48 p.m. ET

Questions and Answers

AAN.com/21AM

SCIENTIFIC SESSIONS

2:24 p.m. ET

S16 Neuro-oncology

SCIENTIFIC SESSIONS Monday, April 19, 2021 S17 History of Neurology 4:00 p.m. ET

S17.001

4:08 p.m. ET

S17.002

CME

Historical Perspectives of Thrombolysis in Acute Ischemic Stroke Before the Alteplase Era—Jorge Guy Ortiz-Garcia, Ronald Alvarado Dyer, Faddi Ghassan M. Saleh Velez Powdered Human Skulls in New Spain: Epilepsy Care before Pedro de Horta, the First American Epileptologist—Guillermo Ruben Delgado-Garcia, Carolina Rodriguez-Navarez, Bruno Estanol Vidal

4:00 p.m. ET

S18.001

4:08 p.m. ET

S18.002

CME

Sociodemographic and Clinical Characteristics of Patients With Multiple Sclerosis by Race and Ethnicity (NARCRMS Registry) —Victor M. Rivera, Pavle Repovic, Ayo Adeyemi, Arman Altincatal, Coraly Perez Bajandas, Toni Saldana-King, Wanda CastroBorrero

Questions and Answers

Race/ethnicity and Insurance Status Impact Acute Ischemic Stroke Treatment within Three Large U.S. States—Alison Herman, Lindsey Ray Kuohn, Guido Jose Falcone, Richa Sharma, David Y. Hwang, Kevin N. Sheth, Jennifer A. Kim

4:24 p.m. ET

4:16 p.m. ET

SCIENTIFIC SESSIONS

S18 Health Care Disparities

S17.003

The Color of Neurology Workforce—Aminah Abdul Razzack

Questions and Answers

4:24 p.m. ET

S18.003

4:32 p.m. ET

S18.004

Dr. Betty G. Clements: Breaking Gender Barriers in the Air Force and Neurology—Elizabeth A. Coon, Christopher J. Boes

An Assessment of Gender and Racial/Ethnic Diversity amongst Neurology Residents and Physicians—Fabiola Valenzuela, Minerva Romero Arenas

4:48 p.m. ET

4:40 p.m. ET

S18.005

4:32 p.m. ET

S17.004

4:40 p.m. ET

S17.005

Disentangling the Gordian Knot: The Birth, Father, and Future of Balloon Embolization— Victor Ekuta

Questions and Answers

Racial Disparities with Last Known Normal Time in Patients with Acute Ischemic Stroke— Mangala Gopal, Vivien H. Lee

Creation of a Longitudinal, Clinical Undergraduate Pipeline Program to Engage Underrepresented Individuals in Neurology— Robert Ian Thompson-Stone

4:48 p.m. ET

Questions and Answers

40 2021 AAN Annual Meeting

Tuesday, April 20, 2021 S19 Aging and Dementia 2:00 p.m. ET

CME

S19.001

Preliminary Analysis Of BAN2401 Effects On Brain Amyloid And ARIA-E Findings Over 12 Months Of Treatment In The OpenLabel Extension Of The Phase2b Study BAN2401-G000-201 In Subjects With Early Alzheimer’s Disease—Chad J Swanson, Shobha Dhadda, Mark Hodgkinson, David Li, Michio Kanekiyo, June Kaplow, Martin Rabe, Helena Heanue-travers, Robert Gordon, Robert YK Lai, Lynn D. Kramer

2:08 p.m. ET

S19.002

2:16 p.m. ET

Questions and Answers

2:24 p.m. ET

S19.003

History of Psychiatric Disease Inversely Correlates with Age of Onset in Alzheimer’s Disease—Emily Eijansantos, Isabel Allen, Jessica Deleon, Stephanie Grasso, Nicole Rogers, Rian Bogley, David C. Perry, Virginia Sturm, Howard J. Rosen, Lea Grinberg, William Seeley, Bruce L. Miller, Gil Dan Rabinovici, Maria Gorno Tempini, Zachary Miller

2:32 p.m. ET

S19.004

2:40 p.m. ET

S19.005

Breast Cancer Therapies Reduce Risk of Alzheimer’s Disease and Dementia: Clinic to Bench Translation—Greg Lawrence Branigan, Greg Lawrence Branigan, Kathleen Rodgers, Roberta Diaz Brinton Motor Function in Patients with Neuropsychiatric Manifestations of Neurodegenerative Disease Treated with Pimavanserin—Daniel Weintraub, Erin P. Foff, Clive G. Ballard, Bradley W. McEvoy, Bruce Coate, George Demos, Ana Lilliam Berrio, Brandon Abbs, James Maurice Youakim, Srdjan Stankovic

2:48 p.m. ET

Questions and Answers

CME

Amyotrophic Lateral Sclerosis

2:00 p.m. ET

S20.001

2:08 p.m. ET

S20.002

Design of a Phase 3, Randomized, Placebocontrolled Trial of Tofersen Initiated in Clinically Pre-symptomatic SOD1 Mutation Carriers with a Longitudinal Natural History Run-in—Michael G. Benatar, Joanne Wuu, Peter Munch Andersen, Jinsy Andrews, Bob Bucelli, Markus Otto, Toby A. Ferguson, Weiping Chen, Laura Fanning, Danielle Graham, Peng Sun, Yingying Liu, Janice Chun Yee Wong, Stephanie Fradette Clinical Utility of Whole-Genome Sequencing in an ALS Cohort—Adriano Chio, Andrea Calvo, Cristina Moglia, Maura Brunetti, Ruth Chia, Jinhui Ding, J. Raphael Gibbs, Clifton Dalgard, Sonja Waltraud Scholz, Bryan Traynor, Letizia Mazzini, Fabiola De Marchi, Lucia Corrado, Sandra D'Alfonso, Maurizio Grassano

2:16 p.m. ET

Questions and Answers

2:24 p.m. ET

S20.003

2:32 p.m. ET

S20.004

2:40 p.m. ET

S20.005

Determinants of Clinical Response to Levosimendan in the REFALS pPhase 3 Study in People with ALS—Merit E. Cudkowicz, Angela L. Genge, Nicholas J. Maragakis, Susanne Petri, Leonard H. Van den Berg, Valtteri Aho, Chris Garratt, Toni Sarapohja, Ammar Al-Chalabi Metabolic Brain Changes Across Different Levels Of Cognitive Impairment In ALS: A 18F-FDG-PET Study—Antonio Canosa, Cristina Moglia, Umberto Manera, Rosario Vasta, Maria Claudia Torrieri, Vincenzo Arena, Fabrizio D'Ovidio, Francesca Palumbo, Jean Pierre Zucchetti, Barbara Iazzolino, Laura Peotta, Andrea Calvo, Marco Pagani, Adriano Chio WVE-004, An Investigational Stereopure Antisense Oligonucleotide for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) —Yuanjing Liu, Amy Andreucci, Elena Dale, Yuan Yin, Hailin Yang, Fangjun Liu, Saurabh Patil, Susovan Mohapatra, Erin Purcell-Estabrook, Kristin Taborn, Elena Dale, Chandra Vargeese

2:48 p.m. ET

Questions and Answers

AAN.com/21AM

SCIENTIFIC SESSIONS

A Comparative Study of Plasma t-tau and Neurofilament Light Chain in Frontotemporal Lobar Degeneration and Alzheimer’s Disease— Ignacio Illan-Gala, Alberto Lleo, Adam Staffaroni, Henrik Zetterberg, Agnieszka Kieloch, Lea Grinberg, Salvatore Spina, Joel Kramer, Eliana Marisa Ramos, Giovanni Coppola, Renaud La Joie, Gil Dan Rabinovici, David C. Perry, Maria Gorno Tempini, William Seeley, Bruce L. Miller, Howard J. Rosen, Adam L. Boxer, Julio C. Rojas -Martinez

S20 Motor Neuron Disease/

SCIENTIFIC SESSIONS Tuesday, April 20, 2021 S21 Neuroepidemiology 2:00 p.m. ET

S21.001

2:08 p.m. ET

S21.002

CME

Effect Of Linoleic Acid On Ischemic Stroke: A Mendelian Randomization Study—David Wu, Huijun Huang, Yu Qian, Yingying Mao Midlife Cardiac Structure And Function Are Associated With Lower Midlife Cognition: The CARDIA Study—Laure Rouch, Laure Rouch, Feng Xia, Stephen Sidney, Joao Lima, Kristine Yaffe

2:16 p.m. ET

Questions and Answers

SCIENTIFIC SESSIONS

2:24 p.m. ET

S21.003

Anomalously Warm Weather and Acute Care Visits in Patients with Multiple Sclerosis: A Retrospective Study of Privately Insured Individuals in the U.S.—Holly Elser, Robbie Parks, Nuriel Moghavem, Mathew Kiang, Nina Bozinov, Victor W. Henderson, David Rehkopf, Joan Casey

2:32 p.m. ET

S21.004

COVID-19 Outcomes in Hospitalized Patients with Pre-existing Neurodegenerative Diseases in Chicagoland Area—Roshni A. Patel, Glenn Thurston Stebbins, Brandon Barton

2:40 p.m. ET

S21.005

Persistent Chemosensory Dysfunction Associated with COVID-19 Infection in a Cohort of over 800 Health Care Workers—Nicholas Bussiere, Jie Mei, Mathieu Blais, Francois Gros-Louis, Gaston De Serres, Nicolas Dupre, Johannes Frasnelli

2:48 p.m. ET

Questions and Answers

S22 Cerebrovascular Disease and

CME

Interventional Neurology: Biomarkers, Mechanisms of Axonal Injury, Stroke, and Infection

2:00 p.m. ET

S22.001

2:08 p.m. ET

S22.002

Retinal Microvascular Changes and Vessel Diameters are Moderately Associated with Positive Magnetic Resonance Diffusion Weighted Imaging (MR-DWI) among Patients Presenting to the Emergency Department (ED) with Suspected TIA: The FOTO-TIA Study—Beau Benjamin Bruce, Samuel Bidot, Fadi B. Nahab, Jeffery Siegelman, Kaitlin Sandor, Mung Yan Lin, Benjamin Meyer, Michael Ross, David W. Wright, Valerie Biousse, Nancy J. Newman What are the Molecular Mechanisms of Axonal Degeneration in Stroke?—Jack Tzu-Chieh Wang

2:16 p.m. ET

Questions and Answers

2:24 p.m. ET

S22.003

2:32 p.m. ET

S22.004

2:40 p.m. ET

S22.005

Significant Increase in Mortality and Risk of Acute Ischemic Stroke in Infective Endocarditis Patients with Subarachnoid Hemorrhage—Tolga Sursal, Zafar Karimov, Andrew Nazarenko, Linda Ye, Fawaz Al-Mufti Global Frequency of Stroke in Tuberculous Meningitis: A Systematic Review and Metaanalysis—Marie Charmaine Sy, Marie Charmaine Sy, Jose Leonard R Pascual Dental Caries Associated with Incident Ischemic Stroke: Atherosclerosis Risk In Communities Study—Souvik Sen, James Curtis, David Hicklin, Cindy Nichols, Wayne Rosamond, Rebecca F. Gottesman, Kevin Moss, Kimon Divaris, James Beck, Steven Offenbacher

2:48 p.m. ET

Questions and Answers

42 2021 AAN Annual Meeting

S23 Research Methodology and

CME

Education

4:00 p.m. ET

S23.001

Feasibility and Short-Term Outcomes of the MGH Youth Neurology Education and Research Program—Madison Ellin, Alazar Ayele, Johanna Jobin, Jennifer Peak Rubin, Nicte I. Mejia

4:08 p.m. ET

S23.002

Extending the Duration of the Neurology Clerkship – Does it Matter?—Jorge Eduardo Patino Murillas, Zafer Keser, Yvo Andres RodriguezLinares, Rachel Cantu Beck, Luke Kupcha, Louise D. McCullough, Stefano Sandrone, Erin Furr-Stimming

4:16 p.m. ET

Questions and Answers

4:24 p.m. ET

S23.003

4:32 p.m. ET

S23.004

4:40 p.m. ET

S23.005

A Roadmap to Patient Engagement: FSHD and the ReSolve Clinical Trial—Samantha Jo LoRusso, Katy Eichinger, Kiley Higgs, Leann Lewis, Michaela Walker, Alrabi Tawil, Jeffrey Statland, Kim Kimminau Industry-related Financial Conflicts of Interest Amongst Authors of Neurology Clinical Practice Guidelines—Ian Fladie, Bryan Wright, Nathaniel Michael Robbins, Matt Vassar

4:48 p.m. ET

Questions and Answers

CME

Targeted Therapy in Chronic Pain Disorders

4:00 p.m. ET

S24.001

4:08 p.m. ET

S24.002

Peripheral Neurological Safety of Subcutaneous Tanezumab versus Placebo or NSAIDs in Patients with Osteoarthritis—Mark T. Brown, Paola Sandroni, Kenneth C. Gorson, Phillip A. Low, David Hunter, Glenn C. Pixton, Robert Fountaine, Lars Viktrup, Elizabeth Johnston, Christine R. West, Kenneth M. Verburg Role of HINT1 in Neuropathic Pain: Insights Provided by Studies on the Spared Nerve Injury Model and HINT1 Inhibition—Rishi Sharma, Cristina Peterson, Kelley Kitto, Carolyn Fairbanks, Carston Wagner, George Wilcox

4:16 p.m. ET

Questions and Answers

4:24 p.m. ET

S24.003

4:32 p.m. ET

S24.004

4:40 p.m. ET

S24.005

Reduction in Pain During and Between Attacks in Patients with Acute Hepatic Porphyria Treated with Givosiran: A Post-Hoc Analysis of the Phase 3 ENVISION Study—Susana Monroy, Raili Kauppinen, Hung-Chou Kuo, Jeeyoung Oh, Ole Hother-Nielson, Mary-Jean Fanelli, Zhaowei Hua, Qiuling He, John Ko, Amy Simon, David Rees Conus Medullaris Syndrome and Cauda Equina Syndrome after Lumbar Epidural Steroid Injection: A Systematic Review of Literature— Aimen Vanood, Bhavneet Singh, Katherine Elizabeth Wheeler, Gustavo A. Patino Exploratory Study of Acoustic Neuromodulation Improves Pain, Autonomic Function, and Symptoms of Insomnia, Stress, and Anxiety in Individuals with Chronic Pain—Catherine Tegeler, Lindsay Joanna Howard, Kenzie Brown, Dawn Kellar, Faiza Asif-Fraz, Lee Gerdes, Charles H. Tegeler, Hossam Shaltout

4:48 p.m. ET

Questions and Answers

AAN.com/21AM

SCIENTIFIC SESSIONS

Adult Neurology Rotations for Child Neurology Residents: Exploring the Resident Perspective—Stella Deng, Cullen Spencer Marshall, Donald Gilbert, Hannah Jackson, David Wolf, Robert Ian Thompson-Stone

S24 Pain and Palliative Care:

SCIENTIFIC SESSIONS Tuesday, April 20, 2021 S25 MS and CNS Inflammatory

Wednesday, April 21, 2021

CME

Disease: Emerging Therapeutics and Biomarkers

4:00 p.m. ET

S25.001

4:08 p.m. ET

S25.002

SCIENTIFIC SESSIONS

Associations of Serum Neurofilament Light Chain with Clinico-Radiological Characteristics in the MSPATHS Network: A Cross-Sectional Evaluation—Elias S. Sotirchos, Kathryn Fitzgerald, Matthew Smith, James Rhys Williams, Carl DeMoor, Suzanne Szak, Carol Singh, Elizabeth Fisher, Robert A. Bermel, Carrie Michelle Hersh, Megan Hyland, Lauren B. Krupp, Xavier Montalban, Robert T. Naismith, Jacqueline Ann Nicholas, Manuel Comabella Lopez, Tjalf Ziemssen, Ellen M. Mowry, Peter A. Calabresi Brain-homing B cells in Multiple Sclerosis: Association with Bruton’s Tyrosine Kkinase and Targeting by Evobrutinib—Liza Rijvers, Marie-Jose Melief, Jamie Van Langelaar, Rudi Hendriks, Ursula Boschert, Roland Grenningloh, Joost JFM Smolders, Marvin Van Luijn

4:16 p.m. ET

Questions and Answers

4:24 p.m. ET

S25.003

Establishing a Role for the Bruton’s Tyrosine Kinase Inhibitor Tolebrutinib in Modulating Neuroinflammation and Disease Progression in MS—Ross C. Gruber, Michael R Dufault, Nathalie Chretien, Jonathan Proto, Mindy Zhang, Evis Havari, Timothy J. Turner, Anthony Chomyk, Emilie Christie, Bruce D. Trapp, Dimitry Ofengeim

4:32 p.m. ET

S25.004

Efficacy and Safety of Tolebrutinib in Patients With Highly Active Relapsing MS: Subgroup Analysis of the Phase 2b Study—Sana Syed, Nicole L. Yonkers, Christopher C. LaGanke, William David Honeycutt, Anthony Traboulsee, Daniel R. Wynn, Sibyl E. Wray, Petr Prochazka, Deborah Dukovic, Timothy J. Turner

4:40 p.m. ET

S25.005

The Safety of Fenebrutinib in a Large Population of Patients With Diverse Autoimmune Indications Supports Investigation in Multiple Sclerosis (MS) —Jiwon Oh, Stanley L. Cohen, David Isenberg, Marcus Maurer, Joshua Galanter, Tom Chu, Anastasia Teterina, Alexandra L. Goodyear, Corey Mandel, Chin Lee, Katie Tuckwell, Jeremy Lim, Konstantina Vanevski, Gavin Giovannoni

4:48 p.m. ET

Questions and Answers

44 2021 AAN Annual Meeting

S26 Neurocritical Care 2:00 p.m. ET

S26.001

2:08 p.m. ET

S26.002

CME

Higher Systolic Blood Pressure Variability After Endovascular Thrombectomy Is Associated with Poor Functional Outcome—Ayush Prasad, Jessica Kobsa, Sreeja Kodali, Cindy Khanh Phuong Nguyen, Darko Ernesto Quispe Orozco, Mudassir Farooqui, Cynthia Zevallos, Santiago Ortega Gutierrez, Mohammad Anadani, Eyad Almallouhi, Joontae Kim, Ilko Maier, Nolwenn Riou-Comte, Stacey Wolfe, Patrick Brown, Kyle Fargen, Eva Mistry, Hiba Fakhri, Akshitkumar Mistry, Ka-Ho Wong, Adam De Havenon, Fabio Nascimento, Kevin N. Sheth, Nils Petersen Post-Intensive Care Syndrome Impacts Quality of Life in Critically Ill Stroke Patients—Kelsey Cacic, Natalie Kreitzer, Neha Dangayach, E. Wesley Ely, Brandon P. Foreman

2:16 p.m. ET

Questions and Answers

2:24 p.m. ET

S26.003

2:32 p.m. ET

S26.004

2:40 p.m. ET

S26.005

Shared Decision-making in Goals-of-care Meetings for Critically Ill Neurologic Patients: A Multi-center Study—Abhinav Vibhas Prasad, Connie Ge, Kelsey Goostrey, Beshoy Armanios, Praewpannanrai Buddadhumaruk Sun, Catherine L Hough, Jay Steingrub, Douglas White, Susanne Muehlschlegel A Machine Learning Algorithm for Predicting Outcome after Subarachnoid Hemorrhage—Hsin Yi Chen, Wei-Long Zheng, Sahar Fatima Zafar, Jonathan Elmer, Manohar Ghanta, Valdery Moura, Aman Patel, Eric Rosenthal, Emily Jean Gilmore, M. Brandon Westover, Jennifer A. Kim von Willebrand Factor (vWF) as a Biomarker of Traumatic Brain Injury—Rachel Elizabeth Thomas, Joshua Gatson, Erika Silverman, Leroy Wesley, My Duyen Le, Justin Alexander Morrison, Cian Dabrowski, Brigid Anne Magdamo, Jeff Debad, Christopher Campbell, Danielle Sandsmark, Ramon R. Diaz-Arrastia

2:48 p.m. ET

Questions and Answers

S27 Movement Disorders: Basic

CME

Science

2:00 p.m. ET

S27.001

2:08 p.m. ET

S27.002

Antigen-presenting Cells from PD Patients Exhibit an Autoinflammatory Cytokine Profile—Camille Michaud, Camberly Hernandez, Annie Laplante, Sebastien Audet, Renaud Balthazard, Martine Tetreault, Diana Matheoud The Role of Mitochondrial Antigen Presentation in the Establishment of Parkinson's Diseaselike Symptoms—Moustafa Nouh Badr, Renaud Balthazard, Annie Laplante, Diana Matheoud

2:16 p.m. ET

Questions and Answers

2:24 p.m. ET

S27.003

2:00 p.m. ET

S28.001

2:08 p.m. ET

S28.002

Different Disease Modifying Therapies Can Increase or Decrease Covid-19 Severity in Multiple Sclerosis—Maria Pia Sormani, Nicola De Rossi, Irene Schiavetti, Luca Carmisciano, Cinzia Cordioli, Lucia Moiola, Marta Radaelli, Paolo Immovilli, Marco Alfonso Narduc Capobianco, Maria Trojano, Paola Zaratin, Gioacchino Tedeschi, Giancarlo Comi, Mario Battaglia, Francesco Patti, Marco Salvetti

2:16 p.m. ET

Questions and Answers

S27.004

2:24 p.m. ET

S28.003

2:40 p.m. ET

S27.005

2:32 p.m. ET

S28.004

2:40 p.m. ET

S28.005

Essential Tremor versus “ET-plus”: A Postmortem Study—Elan D. Louis, John Gionco, Whitney Hartstone, Regina Martuscello, Sheng-Han Kuo, Phyllis Faust

2:48 p.m. ET

Questions and Answers

Identifying Distinct Cognitive Phenotypes in Multiple Sclerosis—Ermelinda De Meo, Emilio Portaccio, Antonio Giorgio, Luis Ruano, Benedetta Goretti, Claudia Niccolai, Francesco Patti, Clara Chisari, Paolo Gallo, Paola Grossi, Angelo Ghezzi, Marco Roscio, Flavia Mattioli, Chiara Stampatori, Marta Simone, Rosa G. Viterbo, Raffaello Bonacchi, Maria Assunta Rocca, Nicola De Stefano, Massimo Filippi, Maria Pia Amato

2:32 p.m. ET

ATH434 Preserves Dopaminergic Neurons, Reduces a-synuclein Oligomerization, and Improves Motor Function in a Transgenic Murine Multiple System Atrophy Model—Antonio HeraGarvin, Violetta Refolo, Margaret Bradbury, David A. Stamler, Nadia Stefanova

CME

Determinants of Recovery from the Coronavirus Disease 2019 in People with Multiple Sclerosis: The UK MS Register COVID-19 Prospective Cohort Study—Afagh Garjani, Richard St. John Nicholas, Rod Middleton, Katherine Tuite-Dalton, Rachael Hunter, Roshan Das Nair, Nikolaos Evangelou Delay from Treatment Start to Full Effect of Immunotherapies for Multiple Sclerosis—Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J William L. Brown, Dana Horakova, Eva Havrdova, Maria Trojano, Francesco Patti, Guillermo Izquierdo Ayuso, Sara Eichau Madue&ntilde;o, Marco Onofrj, Alessandra Lugaresi, Alexandre Prat, J M. Girard, Pierre Grammond, Patrizia Sola, Diana Ferraro, Serkan Ozakbas, Roberto Bergamaschi, Maria Jose Sa, Elisabetta Cartechini, Cavit Boz, Franco Granella, Raymond Hupperts, Murat Terzi, Jeannette LechnerScott, Daniele Litterio A. Spitaleri, Vincent Van Pesch, Aysun Soysal, Javier Olaskoaga, Julie Prevost, Eduardo Aguera Morales, Mark Slee, Tunde Csepany, Recai Turkoglu, Youssef Sidhom, Riadh Gouider, Bart Van Wijmeersch, Pamela Ann McCombe, Richard A L Macdonell, Alasdair Coles, Charles Malpas, Helmut Butzkueven, Sandra Vukusic, Tomas Kalincik Early Clinical and MRI Predictors of Longterm Disability in Pediatric Multiple Sclerosis Patients—Ermelinda De Meo, Raffaello Bonacchi, Lucia Moiola, Francesca Sangalli, Bruno Colombo, Giancarlo Comi, Vittorio Martinelli, Maria Assunta Rocca, Maria Pia Amato, Massimo Filippi

2:48 p.m. ET

Questions and Answers AAN.com/21AM

SCIENTIFIC SESSIONS

SV2C is Required for Nicotine-mediated Rescue of Alpha-synuclein Neurotoxicity—Sabrina Clemens, Abby Lauren Olsen

S28 Clinical Decision Making in MS

SCIENTIFIC SESSIONS Wednesday, April 21, 2021 S29 Autoimmune Neurology: Clinical

CME

Trials, Treatment, and Diagnosis of CNS and PNS Autoimmune Neurologic Disorders

4:00 p.m. ET

S29.001

Topline Results of a Phase 2 Study of Subcutaneous IMVT-1401 in Patients with Generalized Myasthenia Gravis—Michael G. Benatar, Ari Breiner, Vera Bril, Richard J. Nowak, Imogene Dunn, Alan R. Jacobs

SCIENTIFIC SESSIONS

4:08 p.m. ET

S29.002

Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, PlaceboControlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis—Jeff Guptill, Carlo Antozzi, Vera Bril, Josep Gamez, Sven G. Meuth, Jose Luis Munoz Blanco, Richard J. Nowak, Dianna Quan, Teresa Sevilla, Andrzej Szczudlik, Brooke W Hegarty, Marie-Helene Jouvin, Jim Jin, Santiago Arroyo

4:16 p.m. ET

Questions and Answers

4:24 p.m. ET

S29.003

Pharmacodynamic Modeling and Exposureresponse Assessment of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders—Li Yan, Bing Wang, Dewei She, Benjamin Mitchell, Ryan Criste, Daniel M. Cimbora, Eliezer Katz, William Rees

4:32 p.m. ET

S29.004

Long-term Efficacy and Safety of Eculizumab Monotherapy in AQP4+ Neuromyelitis Optica Spectrum Disorder—Sean J. Pittock, Kazuo Fujihara, Jacqueline Palace, Achim Berthele, Ho Jin Kim, Celia Oreja Guevara, Ichiro Nakashima, Michael Levy, Shulian Shang, Marcus Yountz, Larisa Miller, Roisin Armstrong, Dean M. Wingerchuk

4:40 p.m. ET

S29.005

The Positive Predictive Value of MOG Autoantibody Live Cell-Based Assay in a Tertiary Referral Center—Elia Sechi, Marina Buciuc, Sean J. Pittock, John Chen, James Fryer, Adrian Budhram, Brian G. Weinshenker, Christine Beattie, Andrew McKeon, John R. Mills, Eoin P. Flanagan

4:48 p.m. ET

Questions and Answers

46 2021 AAN Annual Meeting

S30 Cerebrovascular Disease and

CME

Interventional Neurology 3

4:00 p.m. ET

S30.001

4:08 p.m. ET

S30.002

Safety and Efficacy of the Telestroke Dripand-Stay Model: A Systematic Review and Meta-analysis—Hena Waseem, Yasir Salih, Charles Burney, Mark Abel, Natalie Riblet, Nathaniel Michael Robbins Race and Ethnicity Influence Perihematomal Edema Volume in Supratentorial Intracerebral Hemorrhage—Julian Acosta, Yasheng Chen, Cameron Both, Audrey Leasure, Fernando Testai, Daniel Woo, Jin Moo Lee, Kevin N. Sheth, Rajat Dhar, Guido Jose Falcone

4:16 p.m. ET

Questions and Answers

4:24 p.m. ET

S30.003

4:32 p.m. ET

S30.004

4:40 p.m. ET

S30.005

Improved Identification of FAST Stroke Signs in the Population After Multiple Public Awareness Campaigns in Quebec, Canada—Vincent Brissette, Bastien Rioux, Francine Forget Marin, Patrice Lindsay, Alexandre Y. Poppe Stroke Disparities Across Racial and other Minorities: Results from the “All of Us” Research Program—Julian Acosta, Audrey Leasure, Cameron Both, Natalia Szejko, Victor Torres-Lopez, Kevin N. Sheth, Guido Jose Falcone Nationwide Racial Disparities in Smoking Cessation after Stroke in the United States— Neal S. Parikh, Melvin Parasram, Yongkang Zhang, Saad Abdul Sami Mir, Halina White, Babak Navi, Hooman Kamel

4:48 p.m. ET

Questions and Answers

S31 Infectious Disease: Stroke and

CME

Infectious Diseases

4:00 p.m. ET

S31.001

Injection Drug Use and Right-sided Endocarditis - Are We Missing the Strokes?—Karan Hingorani, Erin Barnes, Thiago Santos Carneiro, Pria Anand, Charlene Jennifer Ong, David Young Chung, Ali Daneshmand, Kushak Suchdev, Courtney Takahashi, David M. Greer, Julie Grimes Shulman, Hugo Javier Aparicio, Thanh Ngoc Nguyen, Jose Rafael Romero, Mohamad Abdalkader, Simeon Kimmel, Zoe Weinstein, Maura Fagan, Nikola Dobrilovic, Eric Awtry, Anna Marisa Cervantes-Arslanian

4:08 p.m. ET

S31.002

4:16 p.m. ET

Questions and Answers

4:24 p.m. ET

S31.003

4:32 p.m. ET

S31.004

4:40 p.m. ET

S31.005

Neuropathological Features of COVID-19—Erica Normandin, Shamik Bhattacharyya, Shibani Sharon Mukerji, Kiana Keller, Ahya Sajawal Ali, Gordon Adams, Jason Hornick, Robert Padera, Pardis Sabeti, Isaac H Solomon Cerebral Venous Thrombosis In COVID-19 : A New York City Metropolitan Cohort Study— Fawaz Al-Mufti, Hussein Alshammari, Ramandeep Sahni, Rolla Nouman, Philip Overby, Jared Cooper, Haris Kamal, Katarina B. Dakay, Stephan A. Mayer, Chirag Gandhi Neutrophil-Lymphocyte Ratio Associated with Poor Clinical Outcome after Mechanical Thrombectomy Following Large Vessel Occlusion Stroke in Patients with COVID-19— Fawaz Al-Mufti, Tolga Sursal, Hussein Alshammari, Chirag Gandhi, Stephan A. Mayer

4:48 p.m. ET

Questions and Answers

CME

Neuromuscular Diseases

4:00 p.m. ET

S32.001

4:08 p.m. ET

S32.002

Global Open-label Extension: 24-month Data in Patients with hATTR Amyloidosis—David D. Adams, Alejandra Gonzalez-Duarte, Elizabeth Ann Mauricio, Thomas H. Brannagan, Teresa Coelho, Jonas Wixner, Erhan Berber, Marianne T. Sweetser, Matthew White, Jing Jing Wang, Michael J. Polydefkis Impact of Patisiran on Activities of Daily Living and Functional Status in hATTR Amyloidosis— Amanda C. Peltier, Alejandra Gonzalez-Duarte, John L. Berk, Ivailo Tournev, Ole Suhr, Senda Ajroud-Driss, Madeline Merkel, Hollis Lin, Cecilia Hale, David D. Adams

4:16 p.m. ET

Questions and Answers

4:24 p.m. ET

S32.003

4:32 p.m. ET

S32.004

4:40 p.m. ET

S32.005

Safety, ß-sarcoglycan Expression and Functional Outcomes from Systemic Gene Transfer of rAAVrh74.MHCK7.SGCB in Patients with Limb-Girdle Muscular Dystrophy Type 2E (LGMD2E) —Louise R. Rodino-Klapac, Eric Pozsgai, Sarah Lewis, Danielle A. Griffin, Aaron Meadows, Kelly Lehman, Kathleen Church, Natalie Fae Miller, Megan Iammarino, Linda Pax Lowes, Jerry R. Mendell A Multicenter Randomized, Double-Blind, Placebo-Controlled, Gene-Delivery Clinical Trial of rAAVrh74.MHCK7.micro-dystrophin for Duchenne Muscular Dystrophy—Jerry R. Mendell, Perry Shieh, Zarife Sahenk, Kelly Lehman, Linda Pax Lowes, Natalie Fae Miller, Megan Iammarino, Lindsay N. Alfano, Jeremy Woods, Christy Skura, Howard Mao, Loretta Staudt, Rachael Potter, Danielle A. Griffin, Sarah Lewis, Tianle Hu, Sameer Upadhyay, Tejdip Singh, Louise R. Rodino-Klapac AAV Gene Therapy for TNNT1-associated Nemaline Myopathy—Eleonora D'Ambrosio, Monique Otero, Haley Grimason, Lena Labdi, Kevin Strauss, Heather Gray-Edwards, Miguel Esteves

4:48 p.m. ET

Questions and Answers

AAN.com/21AM

SCIENTIFIC SESSIONS

Acute Hospital Outcomes COVID-19 Associated Neurological Dysfunction—Nicole Paul, Aleksandra Safonova, Valeria Altamirano, Michal Hammond, Ali Scott, Aditya Sharma, Abigail Skeel, Charith Ratnayake, Carlos Villamizar Rosales, Sherry Chou

S32 Therapeutics of Genetic

Make KESIMPTA your 1st choice Learn more at KesimptaHCP.com

KESIMPTA and the KESIMPTA logo are registered trademarks of Novartis AG.

Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, New Jersey 07936-1080

2/21

T-KSM-1401237

POSTERS

Virtual posters offer a full gallery of abstracts and the ability to find the research relevant to you by filtering by topic, institution, abstract author, and more. With 26 topics, including a new topic on health care disparities, we have your subspecialty and research interests covered!

Visit posters during the Annual Meeting to ask authors questions during dedicated live video office hours and/or via other interactive chat features. “Tours” will be offered throughout the conference.

Aging and Dementia

Autoimmune Neurology Number of Abstract Theme Posters 10 COVID-19 / SARS-CoV-2 Associated Autoimmune Neurologic Syndromes 9 Advances in Neuromyelitis Optica Spectrum Disorders (NMOSD) 10 Advances in Antibody Associated PNS and CNS Autoimmune Neurologic Disorders 10 Autoimmune Encephalitis: Treatment, Biomarkers, and Prognosis 10 Neuro-Rheumatologic Disorders, Cancer Immunotherapy, and Transverse Myelitis 10 Advances in MOG Antibody Disease 10 Inflammatory Neuropathies and Stiff Person Syndrome 10 Expanding Phenotypes of Neuronal Autoantibody Associated Neurological Disorders 37 Clinical Observations and Advances

Autonomic Disorders Number of Posters 7

Abstract Theme Autonomic Disorders

Number of Abstract Theme Posters 7 COVID-19 9 Neurodegenerative Disorders 12 Imaging and Other Topics 8 Assessments 13 Case Series and Unusual Cases

Cerebrovascular Disease and Interventional Neurology Number of Abstract Theme Posters 28 COVID-19 and Stroke 26 Endovascular Treatment 15 Emergency Evaluation and Thrombolysis 23 Intracerebral Hemorrhage and Subdural Hematoma 15 SAH, Aneurysm, and Other Vascular Malformations 5 Pre-hospital Evaluation and Treatment 9 In-patient Evaluation and Treatment 20 Neuro-Cardio 14 Stroke Prevention, Risk Factors, and Community Education 11 Telestroke 10 Health Care Disparities and Stroke Epidemiology 7 Imaging and Localization 13 Biomarkers, Genetics, and Animal Models 12 Post Stroke Complications, Recovery, and Outcomes 9 Systemic Disease and Stroke 39 Unusual Stroke Etiology, Presentation, and Treatments 13 Vasculopathy and Disorders of Cerebral Autoregulation

AAN.com/21AM

POSTERS

Number of Abstract Theme Posters 10 Basic Science and Genetics 9 Clinical Trials 10 Frontotemporal Dementia 10 Dementia Risk Factors 10 Neuroimaging 9 Biomarkers 10 Neuropsychology 10 Alzheimer’s Disease and Non-Alzheimer’s Dementia 10 Neuropsychiatric Symptoms, Goals of Care, and Education 10 Clinical and Neuropathological Aspects

Behavioral and Cognitive Neurology

POSTERS Child Neurology and Developmental Neurology Number of Abstract Posters Theme 7 Emergency Department and Hospital Based Care 7 Headache, Neonatology, Neurophysiology, and Clinical Trials 13 Neurogenetics and Neurodevelopmental Disorders 9 Neurogenetics and Clinical Trials 8 Neurogenetics and Clinical Trials 7 Neurogenetics and Metabolism 7 Infectious and Inflammatory Conditions 11 Neuromuscular Disorders and Clinical Trials 11 Neuromuscular Disorders and Clinical Trials 10 Epilepsy

General Neurology Number of Abstract Theme Posters 10 Advances in Diagnostics 10 Neurological Impact of COVID-19 9 Vascular Studies and Case Reports 10 Teleneurology and Education 10 Health Services and Outcomes 10 Neuromuscular Studies and Case Reports 10 Imaging and Encephalopathy 10 Clinical Studies and Case Reports 10 Medication and Pharmacology 9 Drug Therapies and Clinical Trials

Global Health Number of Posters

POSTERS

Abstract Theme Global Health

Epilepsy/Clinical Neurophysiology (EEG) Number of Abstract Posters Theme 26 Antiseizure Medication: Clinical Trials 11 EEG 12 Semiology and PNES 7 Clinical Epilepsy: COVID-19 9 Clinical Epilepsy: Neuromodulation 9 Genetics 12 Clinical Epilepsy 10 Clinical Epilepsy: Other 12 Status Epilepticus and Epilepsy Surgery 11 Antiseizure Medication 8 Clinical Epilepsy: Co-morbidities 9 Antiseizure Medication: Rescue 7 Clinical Epilepsy: Neuroimaging

Headache Number of Posters

Abstract Theme

9 Clinical Trials 1 8 Clinical Trials 2 10 Clinical Trials 3 10 Clinical Trials 4 10 Clinical Trials 5 9 Epidemiology 10 Neuroimaging and Preclinical 10 Clinical Observations I 10 Case Reports 10 Acute Care and Medication Overuse 10 Neuralgias and Preclinical 10 Clinical Trials VI 10 Real-World Experience with Therapeutics 10 Treatment Safety and Outcomes 10 Clinical Observations II

Health Care Disparities Be sure to check out the newly added education course: Hot Topics in Clinical Practice: Anti-amyloid Therapy for Alzheimer's Disease Monday, April 19, 6:00 p.m.–7:00 p.m. ET Director: Melissa Yu, MD, FAAN

50 2021 AAN Annual Meeting

Number of Posters 10 10

Abstract Theme Health Care Disparities 1 Health Care Disparities 2

History of Neurology Number of Posters 8

Abstract Theme History of Neurology

Infectious Disease Number of Posters

Abstract Theme

Movement Disorders Number of Posters

Abstract Theme

9 Dystonia 10 Essential and Other Tremors 10 Ataxia and Cerebellar Disorders 10 Dyskinesia, Tics, Spasticity, and Myoclonus 10 Huntington's Disease 18 Parkinson's Disease: Non-motor Symptoms 19 Parkinson's Disease: Motor Symptoms 10 Movement Disorders Genetics 18 Deep Brain Stimulation 10 Deep Brain Stimulation and Other Device and Surgical Therapies 29 Clinical Trials, Surveys, and Studies in Movement Disorders 10 Movement Disorders: Imaging 9 Basic Science and Other Clinical Movement Disorders 7 Movement Disorders: Epidemiology 7 Atypical Parkinsonisms

Number of Posters

Abstract Theme

9 Biomarkers 12 COVID-19 30 MS Clinical Assessments and Outcome Measures 20 MS Clinical Practice and Decision Making 39 MS Clinical Trials and Therapeutics 10 MS Epidemiology 18 MS Immunology and Basic Science 30 MS Neuroimaging 10 MS Special Populations: Pregnancy and Pediatrics 15 MS Symptom Assessment and Management 34 MS Therapeutics MOA and Safety 15 MS Health Care System/Policy Based Research 8 MS Prognosis

Neuro Trauma and Sports Neurology Number of Posters 13

Abstract Theme Sports Neurology and Neuro Trauma

Neurocritical Care Number of Posters

Abstract Theme

9 Neurocritical Care: Hemorrhagic Stroke 9 Neurocritical Care: Cardiac Arrest 9 Neurocritical Care: Traumatic Brain Injury and Neuromuscular Disease 10 Neurocritical Care: Seizures and Status Epilepticus 9 Neurocritical Care: COVID-19 and Ischemic Stroke 11 Neurocritical Care: Goals of Care and Brain Death Determination

AAN.com/21AM

POSTERS

9 COVID-19: Neuroepidemiology 9 COVID-19: Cerebrovascular Complications 9 NeuroID: Therapeutics 10 Neurovirology 10 NeuroHIV and Neurosyphilis 10 Vascular Complications of Neurologic Infections 10 COVID-19: Neuroinflammatory Syndromes 10 COVID-19: Encephalopathy and Other Syndromes 10 Fungal and Uncommon Bacterial Infections 10 NeuroID and Mimics

MS and CNS Inflammatory Disease

POSTERS Neuroepidemiology Number of Posters

Abstract Theme

17 Neuroepidemiology

Neuromuscular and Clinical Neurophysiology (EMG)

POSTERS

Number of Posters

Abstract Theme

26 Inherited Muscle Disorders 23 Amyotrophic Lateral Sclerosis 10 Spinal Muscular Atrophy/Other Motor Neuron Disorders 30 Peripheral Neuropathy 6 Neuromuscular Biomarkers: Imaging and Neurophysiology 10 Neuromuscular Junction Disorders 10 Acquired Myopathies 10 COVID-19 Related Neuromuscular Complications 8 Immune Mediated/Infectious Neuromuscular Disorders 10 Observational, Genetic, and Neurophysiologic Studies of Neuromuscular Disorders 4 Channelopathies/Congenital MG

Neuro-oncology Number of Posters

Abstract Theme

8 Primary Brain Tumors 9 Neuro-oncology: Clinical Investigations 29 Neuro-oncology: The Power of Case Reports

Neuro-ophthalmology/Neuro-otology Number of Posters 10 10 8

Abstract Theme Health Services Research in Neuroophthalmology and Neuro-otology Neuro-ophthalmology and the Afferent Visual System Neuro-otology and the Efferent Visual System

52 2021 AAN Annual Meeting

Neuro-rehabilitation Number of Posters

Abstract Theme

13 Neuro-rehabilitation: Clinical Science

Pain and Palliative Care Number of Posters 4 5

Abstract Theme Neurophysiology and Clinical Outcomes in Chronic Pain Disorders Comprehensive Palliative Care from the ICU to the Outpatient Setting

Practice, Policy, and Ethics Number of Posters 9 9 8

Abstract Theme Prioritize Patients! Ethics, Dilemmas, Profession, Oh My! Time for Technology!

Research Methodology and Education Number of Posters 10 13 8 12 11

Abstract Theme Undergraduate Medical Education Graduate Medical Education: Pedagogies and Curriculum Graduate Medical Education: Learning Environment Education Innovation in the Pandemic Other Education

Sleep Number of Posters 10 7 6 7

Abstract Theme Insomnia and Treatment Options New Pharmacological Options for Hypersomnia Symptoms Sleep: Cognition and Apnea Update on RBD and RLS; Hypersomnia and Epilepsy

NIGHTTIME NIGHTTIMEDOSING DOSING

DAYTIME DAYTIMECOVERAGE COVERAGE

New Additional Indication

For Parkinson's disease patients with motor complications,1,2

GOCOVRI® COULD MEAN THE DIFFERENCE

GOCOVRI® is now FDA approved to also treat OFF episodes in patients taking levodopa1

BETWEEN GETTING UP

AND GETTING OUT GOCOVRI® is ready when your Parkinson’s disease (PD) patients with dyskinesia or OFF episodes need it.1,2 With a single bedtime dose, high levels of GOCOVRI® are reached by morning before the ﬁrst levodopa dose, providing all-day coverage with levels slowly decreasing in the hours before bedtime.2 In clinical trials, GOCOVRI® reduced PD dyskinesia (primary endpoint) and OFF time and increased GOOD ON time (secondary endpoints).1 * Not an actual patient.

27% DECREASE IN DYSKINESIA 36% DECREASE IN OFF TIME 29% INCREASE IN GOOD ON TIME

10.1-point reduction in UDysRS score (-17.7 GOCOVRI® vs -7.6 placebo) 3†

1-hour decrease (-0.6 GOCOVRI® vs 0.4 placebo) 3,4†

2.4-hour increase (3.8 GOCOVRI® vs 1.4 placebo) 3,4†

GOOD ON time, ON time without troublesome dyskinesia; UDysRS, Uniﬁed Dyskinesia Rating Scale.

Visit GocovriHCP.com to learn more.

*As seen in pooled results of 2 independently positive, pivotal, Phase 3, randomized, placebo-controlled trials (Study 1 and Study 2) in PD patients on levodopa. Study 1, a 24-week study, was conducted in 121 PD patients with dyskinesia (GOCOVRI® [n = 63], placebo [n = 58]). Study 2, a 12-week study, was conducted in 75 PD patients with dyskinesia (GOCOVRI® [n = 37], placebo [n = 38]).1,3 † In Study 1, GOCOVRI® reduced the UDysRS total score by 15.9 points (vs 8.0 with placebo) (P = 0.0009), decreased OFF time by 0.6 hours (vs an increase of 0.3 hours with placebo) (P = 0.0171), and increased GOOD ON time by 3.6 hours (vs 0.8 hours with placebo) (P < 0.0001) from baseline. In Study 2, GOCOVRI® reduced the UDysRS total score by 20.7 points (vs 6.3 with placebo) (P < 0.0001), decreased OFF time by 0.5 hours (vs an increase of 0.6 hours with placebo) (P = 0.0199), and increased GOOD ON time by 4.0 hours (vs 2.1 hours with placebo) (P = 0.0168) from baseline.1

INDICATION GOCOVRI® (amantadine) extended release capsules is indicated: • For the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications • As adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes It is not known if GOCOVRI is safe and effective in children. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS GOCOVRI is contraindicated in patients with creatinine clearance below 15 mL/min/1.73 m2. WARNINGS AND PRECAUTIONS Falling Asleep During Activities of Daily Living and Somnolence: Patients treated with Parkinson’s disease medications have reported falling asleep during activities of daily living. If a patient develops daytime sleepiness during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued or the patient should be advised to avoid potentially dangerous activities. Suicidality and Depression: Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the beneﬁts outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression.

Hallucinations/Psychotic Behavior: Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases. Dizziness and Orthostatic Hypotension: Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose. Withdrawal-Emergent Hyperpyrexia and Confusion: Rapid dose reduction or abrupt discontinuation of GOCOVRI, may cause an increase in the symptoms of Parkinson’s disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech. Avoid sudden discontinuation of GOCOVRI. Impulse Control/Compulsive Behaviors: Patients may experience urges (e.g. gambling, sexual, money spending, binge eating) and the inability to control them. It is important for prescribers to ask patients or their caregivers about the development of new or increased urges. Consider dose reduction or stopping medications. ADVERSE REACTIONS The most common adverse reactions (>10%) were hallucination, dizziness, dry mouth, peripheral edema, constipation, fall, and orthostatic hypotension.

Please see Brief Summary of full Prescribing Information on the adjacent page.

T:7" S:6.875" and hypotension (13%, 1%) Eye disorders: blurred vision (4%, 1%); cataract (3%, 1%); dry eye (3%, 0%) Musculoskeletal and connective tissue disorders: joint swelling (3%, 0%), muscle spasm (3%, 0%) Reproductive system and breast disorders: benign prostatic hyperplasia—all male (6%, 2%) Respiratory, thoracic, and mediastinal disorders: cough (3%, 0%). Other clinically relevant adverse reactions observed at <3% included somnolence, fatigue, suicide ideation or attempt, apathy, delusions, illusions, and paranoia. Difference in the Frequency of Adverse Reactions by Gender in Patients Treated With GOCOVRI Adverse reactions reported more frequently in women (n=46) vs men (n=54) were: dry mouth (22% vs 11%), nausea (13% vs 4%), livedo reticularis (13% vs 0%), abnormal dreams (9% vs 0%), and cataracts (7% vs 0%), respectively. Men vs women reported the following adverse reactions more frequently: dizziness (20% vs 11%), peripheral edema (19% vs 11%), anxiety (11% vs 2%), orthostatic hypotension (7% vs 2%), and gait disturbance (6% vs 0%), respectively. Difference in the Frequency of Adverse Reactions by Age in Patients Treated With GOCOVRI Hallucinations (visual or auditory) were reported in 31% of patients age 65 years and over (n=52) vs 10 % in patients below the age of 65 years (n=48). Falls were reported in 17% of patients age 65 and over vs 8% of patients below age 65. Orthostatic hypotension was reported in 8% of patients age 65 and over compared with 2% of patients below age 65. DRUG INTERACTIONS: Other Anticholinergic Drugs: Products with anticholinergic properties may potentiate the anticholinergic-like side effects of amantadine. The dose of anticholinergic drugs or of GOCOVRI should be reduced if atropine-like effects appear when these drugs are used concurrently. Drugs Affecting Urinary pH: The pH of the urine has been reported to influence the excretion rate of amantadine. Urine pH is altered by diet, drugs (eg, carbonic anhydrase inhibitors, sodium bicarbonate), and clinical state of the patient (eg, renal tubular acidosis or severe infections of the urinary tract). Since the excretion rate of amantadine increases rapidly when the urine is acidic, the administration of urine acidifying drugs may increase the elimination of the drug from the body. Alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse reactions. Monitor for efficacy or adverse reactions under conditions that alter the urine pH to more acidic or alkaline, respectively. Live Attenuated Influenza Vaccines: Due to its antiviral properties, amantadine may interfere with the efficacy of live attenuated influenza vaccines. Therefore, live vaccines are not recommended during treatment with GOCOVRI. Inactivated influenza vaccines may be used, as appropriate. Alcohol: Concomitant use with alcohol is not recommended, as it may increase the potential for CNS effects such as dizziness, confusion, lightheadedness, and orthostatic hypotension, and may result in dose-dumping. USE IN SPECIFIC POPULATIONS: Pregnancy: There are no adequate data on the developmental risk associated with use of amantadine in pregnant women. Based on animal data, it may cause fetal harm. Lactation: Amantadine is excreted into human milk, but amounts have not been quantified. There is no information on the risk to a breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for GOCOVRI and any potential adverse effects on the breastfed infant from GOCOVRI or from the underlying maternal condition. Pediatric Use: Safety and effectiveness of GOCOVRI in pediatric patients have not been established. Geriatric Use: In Phase 3 clinical trials, the mean age of patients at study entry was 65 years. Of the total number of patients in clinical studies of GOCOVRI, 46% were less than 65 years of age, 39% were 65-74 years of age, and 15% were 75 years of age or older. Hallucinations and falls occurred more frequently in patients 65 years of age or older, compared with those less than 65 years of age. No dose adjustment is recommended on the basis of age. GOCOVRI is known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Renal Impairment: GOCOVRI is contraindicated for use in patients with end-stage renal disease (creatinine clearance values lower than 15 mL/min/1.73 m2). A 50% dose reduction of GOCOVRI to a starting daily dose of 68.5 mg daily for a week, followed by a daily maintenance dose of 137 mg is recommended in patients with moderate renal impairment (creatinine clearance between 30 and 59 mL/min/1.73 m2). For patients with severe renal impairment (creatinine clearance between 15 and 29 mL/min/1.73 m2), a daily dose of 68.5 mg is recommended. Overdosage: Deaths have been reported from overdose with amantadine immediaterelease. The lowest reported acute lethal dose was 1 g of amantadine hydrochloride (equivalent to 0.8 g amantadine). Acute toxicity may be attributable to the anticholinergic effects of amantadine. Drug overdose has resulted in cardiac, respiratory, renal, or central nervous system toxicity. Pulmonary edema and respiratory distress (including adult respiratory distress syndrome, ARDS) have been reported with amantadine; renal dysfunction, including increased BUN and decreased creatinine clearance, can occur. Central nervous system effects that have been reported with overdose include agitation, aggressive behavior, hypertonia, hyperkinesia, ataxia, tremor, disorientation, depersonalization, fear, delirium, psychotic reactions, lethargy, and coma. Seizures may be exacerbated in patients with prior history of seizure disorders. Hyperthermia has occurred with amantadine overdose. For acute overdosing, general supportive measures should be employed along with immediate gastric decontamination if appropriate. Give intravenous fluids if necessary. The excretion rate of amantadine increases with acidification of urine, which may increase the elimination of the drug. Monitor patients for arrhythmias and hypotension. Electrocardiographic monitoring may be needed after ingestion because arrhythmias have been reported after overdose, including arrhythmias with fatal outcomes. Adrenergic agents, such as isoproterenol, in patients with an amantadine overdose has been reported to induce arrhythmias. Monitor blood electrolytes, urine pH, and urinary output. Although amantadine is not efficiently removed by hemodialysis, this procedure may be useful in the treatment of amantadine toxicity in patients with renal failure. References: 1. GOCOVRI® (amantadine) [Prescribing Information]. Emeryville, CA: Adamas Pharma LLC; 2021. 2. Hauser RA, Pahwa R, Wargin WA, et al. Pharmacokinetics of ADS-5102 (amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia. Clin Pharmacokinet. 2018;58(1):77-88. 3. Elmer LW, Juncos JL, Singer C, et al. Pooled analyses of phase III studies of ADS- 5102 (amantadine) extended-release capsules for dyskinesia in Parkinson disease. CNS Drugs. 2018;32(4): 387-398. 4. Data on file. Adamas Pharma LLC, Emeryville, CA.

S:9.75"

GOCOVRI® (amantadine) extended release capsules Brief Summary of full Prescribing Information. See full Prescribing Information. Rx Only. INDICATIONS AND USAGE: GOCOVRI® (amantadine) extended release capsules is indicated: • For the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications • As adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes CONTRAINDICATIONS: Contraindicated in patients with creatinine clearance below 15 mL/min/1.73 m2 WARNINGS AND PRECAUTIONS: Falling Asleep During Activities of Daily Living and Somnolence: Patients treated with Parkinson’s disease medications have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes has resulted in accidents. Patients may not perceive warning signs, such as excessive drowsiness, or they may report feeling alert immediately prior to the event. In controlled clinical trials, somnolence and fatigue were reported in 4% vs 1% of patients treated with GOCOVRI or placebo, respectively. Before initiating treatment with GOCOVRI, advise patients of the potential to develop drowsiness and specifically ask about factors that may increase the risk for somnolence with GOCOVRI, such as concomitant sedating medications or the presence of a sleep disorder. If a patient develops daytime sleepiness or episodes of falling asleep during activities that require full attention (eg, driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued. If a decision is made to continue GOCOVRI, patients should be advised not to drive and to avoid other potentially dangerous activities. There is insufficient information to establish whether dose reduction will eliminate episodes of falling asleep while engaged in activities of daily living or daytime somnolence. Suicidality and Depression: In controlled clinical trials, suicidal ideation or suicide attempt was reported in 2% vs 0%; depression or depressed mood 6% vs 1%; confusional state 3% vs 2%; apathy 2% vs 0%, of patients treated with GOCOVRI or placebo, respectively. Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the benefits outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression. Hallucinations/Psychotic Behavior: Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. In controlled trials, the incidence of patients who experienced visual hallucination, auditory hallucination, delusions, illusions, or paranoia was 25% vs 3%; hallucinations caused discontinuation of treatment in 8% vs 0%; of patients treated with GOCOVRI or placebo, respectively. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases. Dizziness and Orthostatic Hypotension: In controlled clinical trials, 29% vs 2% experienced dizziness, syncope, orthostatic hypotension, presyncope, postural dizziness or hypotension; and 3% vs 0% discontinued study treatment because of dizziness, postural dizziness, or syncope; of patients receiving GOCOVRI or placebo, respectively. Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose. Concomitant use of alcohol with GOCOVRI is not recommended. Withdrawal-Emergent Hyperpyrexia and Confusion: A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central dopaminergic tone. Abrupt discontinuation of GOCOVRI may cause an increase in the symptoms of Parkinson’s disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech. If possible, avoid sudden discontinuation of GOCOVRI. Impulse Control/Compulsive Behaviors: Patients can experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge eating, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including GOCOVRI, that increase central dopaminergic tone. In some cases, these urges were reported to have stopped when the dose was reduced or the medication was discontinued. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to specifically ask patients or their caregivers about the development of such urges, and to consider dose reduction or stopping GOCOVRI treatment. ADVERSE REACTIONS: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. GOCOVRI was evaluated in 2 double-blind, placebo-controlled efficacy trials of similar design and population: Study 1 (123 patients) and Study 2 (75 patients). The study population was approximately 56% male and 94% white, with a mean age of 65 years (age range from 34 years to 82 years). The mean duration of levodopa-induced dyskinesia was 4 years (range 0.1 to 14 years). Active treatment started at 137 mg once daily for 1 week, followed by a dose increase to 274 mg once daily. The treatment duration was 25 weeks for Study 1 and 13 weeks for Study 2. Study 1 was stopped prematurely unrelated to safety, with 39/100 patients (safety population) treated with GOCOVRI for 24 weeks. The most common adverse reactions reported in >10% of GOCOVRI-treated patients and more frequently than on placebo were: hallucination, dizziness, dry mouth, peripheral edema, constipation, falls, and orthostatic hypotension. The overall rate of discontinuation because of adverse reactions was 20% vs 8% for patients treated with GOCOVRI or placebo, respectively. Adverse reactions that led to treatment discontinuation in at least 2% of patients were hallucination (8% GOCOVRI vs 0% placebo), dry mouth (3% GOCOVRI vs 0% placebo), peripheral edema (3% GOCOVRI vs 0% placebo), blurred vision (3% GOCOVRI vs 0% placebo), postural dizziness and syncope (2% GOCOVRI vs 0% placebo), abnormal dreams (2% GOCOVRI vs 1% placebo), dysphagia (2% GOCOVRI vs 0% placebo), and gait disturbance (2% GOCOVRI vs 0% placebo). Pooled Analysis of Adverse Reactions Reported for ≥3% of Patients Treated With GOCOVRI 274 mg (n=100) or placebo (n=98), respectively: Psychiatric disorders: visual and/or auditory hallucination (21%, 3%); anxiety and/or generalized anxiety (7%, 3%); insomnia (7%, 2%); depression/depressed mood (6%, 1%); abnormal dreams (4%, 2%); confusional state (3%, 2%) Nervous system disorders: dizziness (16%, 1%); headache (6%, 4%); dystonia (3%, 1%) Gastrointestinal disorders: dry mouth (16%, 1%); constipation (13%, 3%); nausea (8%, 3%); vomiting (3%, 0%) General disorders and administration-site conditions: peripheral edema (16%, 1%); gait disturbance (3%, 0%) Injury, poisoning, and procedural complications: fall (13%, 7%); contusion (6%, 1%) Infections and infestations: urinary tract infection (10%, 5%) Skin and subcutaneous tissue disorders: livedo reticularis (6%, 0%); pigmentation disorder (3%, 0%) Metabolism and nutrition disorders: decreased appetite (6%, 1%) Vascular disorders: orthostatic hypotension, including postural dizziness, syncope, presyncope,

ABSTRACTS OF DISTINCTION

Distinction is awarded to the abstract deemed to be the top in its topic category in quality of study and interest to the neurologic community. Following are the 26 abstracts that have been awarded the merit of distinction in 2021.

Aging and Dementia S19

Tuesday, April 20 2:24 p.m.–2:32 p.m. ET

History of Psychiatric Disease Inversely Correlates with Age of Onset in Alzheimer’s Disease

Autoimmune Neurology S7

Sunday, April 18 2:40 p.m.–2:48 p.m. ET

The Positive Predictive Value of Aquaporin-4 Antibody Live Cell-based Assay in a Tertiary Referral Center Mayra Montalvo, Sean Pittock, Elia Sechi, James Fryer, Andrew McKeon, John Mills, John Chen, Eoin P. Flanagan

Autonomic Disorders Poster

Saturday, April 17, 7:00 a.m. ET– Thursday, April 22, 5:00 p.m. ET

Tuesday, April 20 2:08 p.m.–2:16 p.m. ET What are the Molecular Mechanisms of Axonal Degeneration in Stroke?

S22

Jack Wang

Child Neurology and Developmental Neurology S4

Saturday, April 17 4:32 p.m.–4:40 p.m. ET

Improving Triaging of EEG Referrals for Rule Out Infantile Spasms (ITERIS) Djurdja Djordjevic, Jennifer Tracey, Cristina Go

Epilepsy/Clinical Neurophysiology (EEG) S1

Saturday, April 17 2:00 p.m.–2:08 p.m. ET

Fetal Antiseizure Medication Effects on Neuropsychological Outcomes at Age 3 Years in the MONEAD Study

Immunogenetic Risk Markers in Postural Orthostatic Tachycardia Syndrome

Kimford Meador, Morris Cohen, David Loring, Carrie Brown, Chelsea Robalino, Page Pennell

Zachary Orban, Amanda Miller, Kate Bourne, Juliana Nitis, Willie Hu, Ruth Reinsel, Lauren Stiles, Artur Fedorowski, Jonas Axelsson

General Neurology

Behavioral and Cognitive Neurology April 19 S14 Monday, 2:00 p.m.–2:08 p.m. ET

Cortical Microstructure in Primary Progressive Aphasia: A Multicenter Study Ignacio Illan-Gala, Victor Montal, Sergi BorregoEcija, Neus Falgàs, Maria Luisa Mandelli, Ariane E Welch, Jordi Pegueroles, Daniel Alcolea Rodriguez, María Belén Sánchez-Saudinós, Jordi Clarimón, Nuria Bargalló, Sofía González-Ortiz, Albert Lladó, Rafael Blesa, Howie Rosen, Bruce Miller, Maria Luisa Gorno Tempini, Raquel Sánchez Valle, Alberto Lleo, Juan Fortea

Clinical April 20 Trials Plenary Tuesday, 10:00 a.m.–12:30 p.m. ET Session Efficacy and Safety Results of the Avalglucosidase alfa Phase 3 COMET Trial in Late-Onset Pompe Disease Patients Hani Kushlaf, Shahram Attarian, Joao Lindolfo Borges, Francoise Bouhour, Yin-Hsiu Chien, YoungChul Choi, Paula Clemens, John Day, Jordi DiazManera, Sevim Erdem-Ozdamar, Ozlem Goker-Alpan, Sergey Illarioshkin, Priya Kishnani, Anna KosteraPruszczyk, Shafeeq Ladha, Tahseen Mozaffar, Mark Roberts, Volker Straub, Antonio Toscano, Ans van der Ploeg, Kristina An Haack, Christopher Hug, Olivier Huynh-Ba, Tianyue Zhou, Judith Johnson, Mazen Dimachkie, Benedikt Schoser AAN.com/21AM

ABSTRACTS OF DISTINCTION

Emily Eijansantos, Isabel Allen, Jessica Deleon, Stephanie Grasso, Nicole Rogers, Rian Bogley, David Perry, Virginia Sturm, Howard Rosen, Lea Grinberg, William Seeley, Bruce Miller, Gil Rabinovici, Maria Gorno Tempini, Zachary Miller

Cerebrovascular Disease and Interventional Neurology

ABSTRACTS OF DISTINCTION Global Health

April 17, 7:00 a.m. ET– Poster Saturday, Thursday, April 22, 5:00 p.m. ET

Longitudinal Analysis of Cognition and Depression in Children and Adolescents with HIV in Zambia Hannah Smith, Gauri Patil, Heather Adams, Esau Mbewe, Pelekelo Kabundula, Sylvia MwanzaKabaghe, Michael Potchen, Gretchen Birbeck, David Bearden

Headache

ABSTRACTS OF DISTINCTION

Clinical April 20 Trials Plenary Tuesday, 10:00 a.m.–12:30 p.m. ET Session Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Preventive Treatment of Migraine Jessica Ailani, Richard Lipton, Peter Goadsby, Hua Guo, Rosa Miceli, Lawrence Severt, Michelle Finnegan, Joel Trugman

Health Care Disparities April 19 S18 Monday, 4:32 p.m.–4:40 p.m. ET

An Assessment of Gender and Racial/ Ethnic Diversity amongst Neurology Residents and Physicians Fabiola Valenzuela, Minerva A. Romero Arenas

History of Neurology S17

Monday, April 19 4:08 p.m.–4:16 p.m. ET

Powdered Human Skulls in New Spain: Epilepsy Care before Pedro de Horta, the First American Epileptologist Guillermo Delgado-Garcia, Carolina RodriguezNavarez, Bruno Vidal

Infectious Disease April 21 S31 Wednesday, 4:24 p.m.–4:32 p.m. ET

Neuropathological Features of COVID-19 Erica Normandin, Shamik Bhattacharyya, Shibani Mukerji, Kiana Keller, Ahya Ali, Gordon Adams, Jason Hornick, Robert Padera, Pardis Sabeti, Isaac H Solomon

56 2021 AAN Annual Meeting

Movement Disorders

April 21 S27 Wednesday, 2:40 p.m.–2:48 p.m. ET

Essential Tremor versus “ET-plus”: A Postmortem Study Elan Louis, John Gionco, Whitney Hartstone, Regina Martuscello, Sheng-Han Kuo, Phyllis Faust

MS and CNS Inflammatory Disease S2

Saturday, April 17 2:00 p.m.–2:08 p.m. ET

Neurite Density Explains Cortical T1-/T2Weighted Ratio in Multiple Sclerosis Paolo Preziosa, Piet M. Bouman, Svenja Kiljan, Martijn D Steenwijk, Alessandro Meani, Petra Pouwels, Maria A. Rocca, Massimo Filippi, Jeroen JG Geurts, Laura Jonkman

Neuro Trauma and Sports Neurology April 17, 7:00 a.m. ET– Poster Saturday, Thursday, April 22, 5:00 p.m. ET

Single Nucleotide Polymorphisms for Calcitonin Gene-related Polypeptide are Related to the Magnitude of Headache Symptoms After Concussion: A Preliminary Observation Michael La Fountaine, Anthony Testa

Neurocritical Care April 21 S26 Wednesday, 2:00 p.m.–2:08 p.m. ET

Higher Systolic Blood Pressure Variability After Endovascular Thrombectomy Is Associated with Poor Functional Outcome Ayush Prasad, Jessica Kobsa, Sreeja Kodali, Cindy Khanh Nguyen, Darko Quispe Orozco, Mudassir Farooqui, Cynthia Zevallos, Santiago Ortega Gutierrez, Mohammad Anadani, Eyad Almallouhi, Joon-Tae Kim, Ilko Maier, Nolwenn Riou-Comte, Stacey Wolfe, Patrick Brown, Kyle Fargen, Eva Mistry, Hiba Fakhri, Akshitkumar Mistry, Ka-Ho Wong, Adam De Havenon, Fabio Nascimento, Kevin Sheth, Nils Petersen

Neuroepidemiology April 20 S21 Tuesday, 2:00 p.m.–2:08 p.m. ET

Effect Of Linoleic Acid On Ischemic Stroke: A Mendelian Randomization Study David Wu, Huijun Huang, Yu Qian, Yingying Mao

Neuromuscular and Clinical Neurophysiology (EMG) Contemporary April 19 Clinical Issues Monday, 10:00 a.m.–12:30 p.m. ET Plenary Session Long-Term Survival of Participants in the CENTAUR Trial of AMX0035 for ALS

Neuro-oncology April 19 S16 Monday, 4:24 p.m.– 4:32 p.m. ET

Adult Pilocytic Astrocytoma in the Molecular Era: Surveying the Prevalence of MAPK Pathway Dysfunction and Overlap with Aggressive Features Timothy A Gregory, Lyndon B Chumbley, Brett J Theeler

Neuro-ophthalmology/Neuro-otology April 17, 7:00 a.m. ET– Poster Saturday, Thursday, April 22, 5:00 p.m. ET

Evaluation of rAAV2/2-ND4 Gene Therapy Efficacy in Leber Hereditary Optic Neuropathy Using an External Control Group of Untreated Patients

Pain and Palliative Care Tuesday, April 20 Clinical Trials Plenary 10:00 a.m.–12:30 p.m. ET Session

Sustained Benefits for 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy - Six Month Results from a Multicenter Randomized Controlled Trial Erika Petersen, Thomas Stauss, James Scowcroft, Elizabeth Brooks, Judith White, Shawn Sills, Kasra Amirdelfan, Maged Guirguis, Jijun Xu, Cong Yu, Ali Nairizi, Denis Patterson, Vincent Galan, Richard Bundschu, Neel Mehta, Dawood Sayed, Shivanand Pramod Lad, David DiBenedetto, Khalid Sethi, Paul Wu, Charles Argoff, Christian Nasr, Rod Taylor, David Caraway, Nagy Mekhail

Practice, Policy, and Ethics April 17, 7:00 a.m. ET– Poster Saturday, Thursday, April 22, 5:00 p.m. ET

Identifying and Understanding Microaggressions among Michigan Medicine African-American Faculty Members Larry Charleston IV

Research Methodology and Education April 20 S23 Tuesday, 4:00 p.m.– 4:08 p.m. ET

Feasibility and Short-Term Outcomes of the MGH Youth Neurology Education and Research Program

Nancy Newman, Patrick Yu-Wai-Man, Valerio Carelli, Madison Ellin, Alazar Ayele, Johanna Jobin, Tara Brady, Nicte Mejia Mark Moster, Catherine Vignal-Clermont, Alfredo Sadun, Chiara La Morgia, Francesco Bandello, Lorena Castillo Campillo, Stéphanie Leruez, Dean Cestari, Rod Sleep Foroozan, Rustum Karanjia, Laure Blouin, Michel Roux, April 18 Magali Taiel, Jose-Alain Sahel S9 Sunday, 2:32 p.m.–2:40 p.m. ET

Neuro-rehabilitation April 17, 7:00 a.m. ET– Poster Saturday, Thursday, April 22, 5:00 p.m. ET

Real-life Data on the Time to Retreatment with Botulinum Toxin A in Upper Limb Spasticity Management

Cutaneous Alpha-Synuclein is Correlated with Autonomic Impairment in Isolated REM Sleep Behavior Disorder Mitchell Miglis, Jennifer Zitser-Koren, Sharika Rajan, Emmanuel During, Logan Schneider, Safwan Jaradeh, Roy Freeman, Christopher Gibbons

AAN.com/21AM

ABSTRACTS OF DISTINCTION

Sabrina Paganoni, Suzanne Hendrix, Samuel Dickson, Newman Knowlton, Eric Macklin, Josh Cohen, Justin Klee, Kent Leslie, Patrick Yeramian, Merit Cudkowicz

Jorge Jacinto, Stephen Ashford, Klemens Fheodoroff, Allison Brashear, Pascal Maisonobe, Andreas Lysandropoulos, Lynne Turner-Stokes

EXCLUSIVE VIRTUAL GOLD PROGRAMS BY TOPIC

Upgrade to Virtual Gold Registration for the best value with Annual Meeting On

Demand. You’ll get exclusive extended access through March 31, 2022,

EXCLUSIVE VIRTUAL GOLD PROGRAMS BY TOPIC

to all programming available through standard registration, the ability to claim additional CME, plus access to the below bonus sessions. The following sessions offer 1 CME each. The program is subject to change. Visit AAN.com/2021Program for the most up-to-date information and more detail on each program. Member Type

Upgrade Cost

Student / Junior / Intern

$79

APP / Business Administrator / Researcher

$169

Neurologist / Physician Affiliate / Senior / Honorary

$239

Nonmember

$379

Best Value

Aging, Dementia, Cognitive, and Behavioral Neurology

Epilepsy/Clinical Neurophysiology (EEG)

Behavioral Neurology

Clinical Epilepsy 2: Advanced

Autoimmune Neurology

Clinical EEG 2

Neuro-rheumatology: Neurologic Manifestations of Systemic Inflammatory and Autoimmune Disease

General Neurology

Cerebrovascular Disease and Interventional Neurology

Neurologic Complications of Medical Disease

Cerebrovascular Disease Prevention Maximizing Quality of Life in Serious Neurologic Illnesses Telestroke

Child Neurology and Developmental Neurology Neurogenetics Treatment of Pediatric Multiple Sclerosis in the Current Era Update in Child Neurology 2 58 2021 AAN Annual Meeting

Neurogenetics

Emergency Neurology: Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room Mitochondrial Disorders in Neurology Good Neurology in Challenging Conditions: Lessons from Military Neurology Clinical Pearls: Learning from Complex Cases: Simple Lessons that Apply to Everyday Problems

Headache

Neuro-ophthalmology/Neuro-otology

Hot Topics in Headaches and Related Disorders

Now You See It, Now You Know It: Pathognomonic Neuro- ophthalmology Examination Findings

Infectious Disease

Ophthalmic Imaging for Neurologists: OCT and Funduscopy in the 21st Century

Emerging Infectious Diseases of the Nervous System

Deep Brain Stimulation Maximizing Quality of Life in Serious Neurologic Illnesses Tourette Syndrome: Assessment and Management

MS and CNS Inflammatory Disease Treatment of Pediatric Multiple Sclerosis in the Current Era Neuromyelitis Optica Spectrum Disorders

Neuro Trauma, Critical Care, and Sports Neurology Emergency Neurology: Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room

Spinal Cord Rehabilitation

Pain and Palliative Care Maximizing Quality of Life in Serious Neurologic Illnesses

Practice, Policy, and Ethics Burnout and Resilience: Strategies and Evidence for Enhancing Well-being Maximizing Quality of Life in Serious Neurologic Illnesses

Sleep Sleep for the Practicing Neurologist: Disordered Sleep in Common Neurologic Diseases

Neuromuscular and Clinical Neurophysiology (EMG) Clinical EMG Small Fiber Neuropathies Maximizing Quality of Life in Serious Neurologic Illnesses

Neuro-oncology Neurologic Consultations in Cancer Patients

AAN.com/21AM

EXCLUSIVE VIRTUAL GOLD PROGRAMS BY TOPIC

Movement Disorders

Neuro-rehabilitation

HELP YOUR ADULT PATIENTS WITH NMOSD

UP FOR AND MAKING IT THEIRS

UPLIZNA

(inebilizumab-cdon) is the first and only FDA-approved B-celldepleting therapy for

NMOSD1

For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

IMPORTANT SAFETY INFORMATION Uplizna® (inebilizumab-cdon) is contraindicated in patients with: • A history of life-threatening infusion reaction to Uplizna

• Active hepatitis B infection

• Active or untreated latent tuberculosis

Warnings and Precautions Infusion Reactions: Uplizna can cause infusion reactions, which can include headache, nausea, somnolence, dyspnea, fever, myalgia, rash, or other symptoms. Infusion reactions were most common with the first infusion but were also observed during subsequent infusions. Administer pre-medication with a corticosteroid, an antihistamine, and an anti-pyretic. Infections: The most common infections reported by Uplizna-treated patients in the randomized and open-label periods included urinary tract infection (20%), nasopharyngitis (13%), upper respiratory tract infection (8%), and influenza (7%). Delay Uplizna administration in patients with an active infection until the infection is resolved. Increased immunosuppressive effects are possible if combining Uplizna with another immunosuppressive therapy. The risk of hepatitis B virus (HBV) reactivation has been observed with other B-cell-depleting antibodies. Perform HBV screening in all patients before initiation of treatment with Uplizna. Do not administer to patients with active hepatitis. References: 1. Uplizna (inebilizumab-cdon) Prescribing Information. Viela Bio, Gaithersburg, MD. 2. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394:1352-1363. doi: 10.1016/S01406736(19)31817-3.

Please see Brief Summary of Prescribing Information on the following page.

IN THE TREATMENT OF NMOSD

Reduce relapses that may lead to permanent disability1,2* RELAPSE

HOSPITALIZATIONS

SAFETY

Significant reduction in the risk of relapse vs placebo

Decreased frequency of hospitalization

Favorable safety profile with adverse event rates similar to placebo

89% of patients were relapse-free through 28 weeks vs 58% for placebo1†

78% relative reduction in the annualized rate of hospitalization1‡

Infusion reactions were seen in <10% of patients taking Uplizna1

A proven twice-yearly§ monotherapy *N-MOmentum was a global, prospective, 3:1 randomized, placebo-controlled study investigating the efficacy and safety of Uplizna 300 mg IV infusion monotherapy. 213 AQP4-IgG seropositive and 17 AQP4-IgG seronegative patients were enrolled. The primary endpoint was time to onset of an NMOSD relapse on or before Day 197. Patients had to have active clinical disease (≥1 NMOSD relapse in the prior year, or ≥2 relapses in the prior 2 years, requiring rescue therapy) and an EDSS score ≤7.5.1,2 HR: 0.227 (95% CI: 0.121, 0.423); P<0.0001; N=213.1

† ‡

0.11 vs 0.5 for placebo.1

Twice-yearly maintenance infusions after initial dosing.1

IMPORTANT SAFETY INFORMATION

Warnings and Precautions (continued)

Although no confirmed cases of Progressive Multifocal Leukoencephalopathy (PML) were identified in Uplizna clinical trials, JC virus infection resulting in PML has been observed in patients treated with other B-cell-depleting antibodies and other therapies that affect immune competence. At the first sign or symptom suggestive of PML, withhold Uplizna and perform an appropriate diagnostic evaluation. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating Uplizna. Vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation, until B-cell repletion. Reduction in Immunoglobulins: There may be a progressive and prolonged hypogammaglobulinemia or decline in the levels of total and individual immunoglobulins such as immunoglobulins G and M (IgG and IgM) with continued Uplizna treatment. Monitor the level of immunoglobulins at the beginning, during, and after discontinuation of treatment with Uplizna until B-cell repletion especially in patients with opportunistic or recurrent infections. Fetal Risk: May cause fetal harm based on animal data. Advise females of reproductive potential of the potential risk to a fetus and to use an effective method of contraception during treatment and for 6 months after stopping Uplizna. Adverse Reactions: The most common adverse reactions (at least 10% of patients treated with Uplizna and greater than placebo) were urinary tract infection and arthralgia. Please see Brief Summary of Prescribing Information on the following page. © 2021 Viela Bio. All rights reserved. US-INEB-2100015 02/21

Brief Summary of Important Information about UPLIZNA® (up-liz’-nah) (inebilizumab-cdon) injection, for intravenous use Indication: Uplizna is a CD19-directed cytolytic antibody indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. Contraindications: Uplizna® (inebilizumab-cdon) is contraindicated in patients with: • Previous life-threatening reaction to infusion of Uplizna • Active hepatitis B infection • Active or untreated latent tuberculosis Warnings and precautions: Infusion Reactions Uplizna can cause infusion reactions, which can include headache, nausea, somnolence, dyspnea, fever, myalgia, rash, or other signs or symptoms. During the randomized clinical trial period, infusion reactions were observed with the first course of Uplizna in 9.3% of NMOSD patients. Infusion reactions were most common with the first infusion but were also observed during subsequent infusions. Reducing the Risk of Infusion Reactions and Managing Infusion Reactions: Administer pre-medication with a corticosteroid, an antihistamine, and an anti-pyretic. Management recommendations for infusion reactions depend on the type and severity of the reaction. For life-threatening infusion reactions, immediately and permanently stop Uplizna and administer appropriate supportive treatment. For less severe infusion reactions, management may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment. Infections An increased risk of infections has been observed with other B-cell-depleting therapies. The most common infections reported by Uplizna-treated patients in the randomized and open-label clinical trial periods included urinary tract infection (20%), nasopharyngitis (13%), upper respiratory tract infection (8%), and influenza (7%). Delay Uplizna administration in patients with an active infection until the infection is resolved. Possible Increased Risk of Immunosuppressant Effects with Other Immunosuppressants: Uplizna has not been studied in combination with other immunosuppressants. If combining Uplizna with another immunosuppressive therapy, consider the potential for increased immunosuppressive effects. Hepatitis B Virus (HBV) Reactivation: Risk of HBV reactivation has been observed with

other B-cell-depleting antibodies. There have been no cases of HBV reactivation in patients treated with Uplizna, but patients with chronic HBV infection were excluded from clinical trials. Perform HBV screening in all patients before initiation of treatment with Uplizna. Do not administer Uplizna to patients with active hepatitis. For patients who are chronic carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment. Progressive Multifocal Leukoencephalopathy (PML): PML is an opportunistic viral infection of the brain caused by the JC virus that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability. Although no confirmed cases of PML were identified in Uplizna clinical trials, JC virus infection resulting in PML has been observed in patients treated with other B-cell-depleting antibodies and other therapies that affect immune competence. In Uplizna clinical trials one subject died following the development of new brain lesions for which a definitive diagnosis could not be established, though the differential diagnosis included an atypical NMOSD relapse, PML, or acute disseminated encephalomyelitis. At the first sign or symptom suggestive of PML, withhold Uplizna and perform an appropriate diagnostic evaluation. MRI findings may be apparent before clinical signs or symptoms. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Tuberculosis: Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating Uplizna. Consider anti-tuberculosis therapy prior to initiation of Uplizna in patients with a history of latent active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consult infectious disease experts regarding whether initiating anti-tuberculosis therapy is appropriate before starting treatment. Vaccinations: Administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of Uplizna. The safety of immunization with live or live-attenuated vaccines following Uplizna therapy has not been studied, and vaccination with live-attenuated or live vaccines is not recommended during treatment and until B-cell repletion. Vaccination of Infants Born to Mothers Treated with Uplizna During Pregnancy: In infants of mothers exposed to Uplizna during pregnancy, do not administer live or live-attenuated vaccines before confirming recovery of B-cell counts in the infant. Depletion of B-cells in these exposed infants may increase the risks from live

or live-attenuated vaccines. Non-live vaccines, as indicated, may be administered prior to recovery from B-cell and immunoglobulin level depletion, but consultation with a qualified specialist should be considered to assess whether a protective immune response was mounted. Reduction in Immunoglobulins There may be a progressive and prolonged hypogammaglobulinemia or decline in the levels of total and individual immunoglobulins such as immunoglobulins G and M (IgG and IgM) with continued Uplizna treatment. Monitor the levels of quantitative serum immunoglobulins during treatment with Uplizna, especially in patients with opportunistic or recurrent infections, and until B-cell repletion after discontinuation of therapy. Consider discontinuing Uplizna therapy if a patient with low immunoglobulin G or M develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. Fetal Risk Based on animal data, Uplizna can cause fetal harm due to B-cell lymphopenia and reduce antibody response in offspring exposed to Uplizna even after B-cell repletion. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other B-cell depleting antibodies during pregnancy. Advise females of reproductive potential to use effective contraception while receiving Uplizna and for at least 6 months after the last dose. Adverse Reactions The safety of Uplizna was evaluated in Study 1, in which 161 patients were exposed to Uplizna at the recommended dosage regimen during the randomized, controlled treatment period; during which 52 patients received placebo. Subsequently, 198 patients were exposed to Uplizna during an open-label treatment period. Two-hundred and eight patients in the randomized and open-label treatment periods had a total of 324 person-years of exposure to Uplizna, including 165 patients with exposure for at least 6 months and 128 with exposure for one year or more. The most common adverse reactions (at least 10% of patients treated with Uplizna and greater than placebo) were urinary tract infection and arthralgia. Adverse reactions in patients with NMOSD with an incidence of at least 5% with Uplizna and a greater incidence than placebo included urinary tract infection (11% vs 10%), arthralgia (10% vs 4%), headache (8% in both arms) and back pain (7% vs 4%). Across both the randomized and open-label treatment, the most common adverse reactions (greater than 10%) were urinary tract infection (20%), nasopharyngitis (13%), infusion reaction (12%), arthralgia (11%), and headache (10%).

Laboratory Abnormalities Decreased Immunoglobulins: At the end of the 6.5-month randomized, controlled period, relative to baseline, the total immunoglobulin level was reduced approximately 8% from baseline for patients treated with Uplizna as compared to an increase of 6% in patients treated with placebo. The mean decreases from baseline in immunoglobulin G (IgG) and immunoglobulin M (IgM) were approximately 4% and 32%, respectively, in patients treated with Uplizna, whereas IgG was increased by 6% and IgM was increased by approximately 13% in placebo-treated patients. The proportion of patients treated with Uplizna who had IgG levels below the lower limit of normal at year 1 was 6.6% and at year 2 was 13%. The proportion of patients treated with Uplizna who had IgM levels below the lower limit of normal at year 1 was 31% and at year 2 was 42%. Decreased Neutrophil Counts: Neutrophil counts between 1.0-1.5 x10 9/L were observed in 6.9% of Uplizna-treated patients versus 1.9% of patients who received placebo. Neutrophil counts between 0.5-1.0 x10 9/L were observed in 1.9% of patients treated with Uplizna compared to no patients who received placebo. At the end of the 6.5-month randomized, controlled period, the proportion of patients with a neutrophil count below the limit of normal was 12% for patients treated with Uplizna compared to 4.2% for patients who received placebo. Decreased Lymphocyte Counts: A reduction in lymphocyte counts was observed more frequently in patients treated with Uplizna compared to those who received placebo. At the end of the 6.5-month randomized, controlled period, the proportion of patients with a lymphocyte count below the limit of normal was 5.3% for patients treated with Uplizna compared to 4.2% for patients who received placebo. Immunogenicity As with all therapeutic proteins there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other inebilizumab products may be misleading. In Study 1, treatment-emergent antibodies (those that appeared or significantly increased from baseline after administration of Uplizna), were detected in 5.6% of patients receiving Uplizna. Although these data do not demonstrate an impact of anti-inebilizumab-cdon antibody development on the efficacy or safety of Uplizna in these patients, the available data are too limited to make definitive conclusions.

Drug interactions: Concomitant usage of Uplizna with immunosuppressant drugs, including systemic corticosteroids, may increase the risk of infection. Consider the risk of additive immune system effects when co-administering immunosuppressive therapies with Uplizna. Use in specific populations: Pregnancy Uplizna is a humanized IgG1 monoclonal antibody and immunoglobulins are known to cross the placental barrier. There are no adequate data on the developmental risk associated with the use of Uplizna in pregnant women. However, transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other B-cell depleting antibodies during pregnancy. B-cell levels in infants following maternal exposure to Uplizna have not been studied in clinical trials. The potential duration of B-cell depletion in such infants, and the impact of B-cell depletion on vaccine safety and effectiveness, is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Animal Data: Intravenous administration of inebilizumab-cdon (0, 3, or 30 mg/kg/week) to human CD19 transgenic (huCD19 Tg) male and female mice prior to and during mating and continuing in females through gestation day 15 resulted in no adverse effects on embryofetal development; however, there was a marked reduction in B cells in fetal blood and liver at both doses tested. These results demonstrate that inebilizumab-cdon crosses the placenta and depletes B cells in the fetus. Intravenous administration of inebilizumab-cdon (0, 3, or 30 mg/kg) to huCD19 Tg mice every three days throughout organogenesis and lactation resulted in depletion of B cells and persistent reductions in immune function (even following repletion of B cells and lasting into adulthood) in offspring at both doses tested. At the end of the lactation period, plasma inebilizumab-cdon levels in offspring were only slightly lower than those in maternal plasma. A no-effect level for immunotoxicity in the offspring was not identified. Lactation There are no data on the presence of inebilizumabcdon in human milk, the effects on a breastfed infant, or the effects on milk production. Human IgG is excreted in human milk, and the potential for absorption of Uplizna to lead to B-cell depletion in the breastfed infant is unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Uplizna and any potential adverse effects on the breastfed infant from Uplizna or from the underlying maternal condition.

Females of Reproductive Potential Women of childbearing potential should use contraception while receiving Uplizna and for 6 months after the last infusion of Uplizna. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Geriatric Use Clinical studies of Uplizna did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Manufactured by: Viela Bio, Inc., 1 Medimmune Way, Gaithersburg, MD 20878 USA U.S. License No. 2129 For more information, go to UPLIZNA.com or call 1-855-558-4352. US-INEB-2100015 02/21

CONFERENCE GUIDELINES The following are guidelines for AAN conferences. Unless specified, these guidelines apply to all AAN conference formats. In addition to the below guidelines, participation in a virtual AAN meeting is subject to AAN’s Privacy Policy. All individuals engaged in any virtual meeting are subject to the AAN.com Code of Conduct, unless otherwise specifically noted. Use of the website and virtual program site(s) is subject to AAN’s Terms of Use. These conference policies are subject to change without notice, at AAN’s discretion. Any changes will be reflected on AAN.com/conferences-community/conference-guidelines. Accreditation/CME ACCME Accreditation The American Academy of Neurology Institute (AANI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AANI holds Accreditation with Commendation, the ACCME highest level of recognition for a CME provider. View the CME Mission Statement on AAN.com. AMA Credit Designation The AANI designates this live activity for a maximum of (*) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. *See individual program descriptions on AAN.com/21AM for the maximum number of credits per program. Claiming CME To claim CME hours, attendees must complete program evaluations. AAN members can access their transcript via NeuroTracker™ at AAN.com/view/NeuroTracker six to eight weeks following the applicable AAN conference. Certificates for Non-physicians Non-physicians participating in AAN programming will receive an acknowledgement of participation indicating attendance at an activity designated for AMA PRA Category 1 Credit(s)™. ABPN Statement The American Board of Psychiatry and Neurology has reviewed the relevant AAN conference and has approved the program as a part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of continuing certification. AMA CME Definition/Educational Content of Certified CME The AMA HOD and the Council on Medical Education have defined continuing medical education as follows: CME consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is the body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public. (HOD policy #300.988)

64 2021 AAN Annual Meeting

Definition of Certified CME • Nonpromotional learning activities certified for credit prior to the activity by an organization authorized by the credit system owner, or • Nonpromotional learning activities for which the credit system owner directly awards credit Accredited CME providers may certify nonclinical subjects (e.g., office management, patient-physician communications, or faculty development) for AMA PRA Category 1 Credit™ as long as these are appropriate to a physician audience and benefit the profession, patient care, or public health. CME activities may describe or explain complementary and alternative health care practices. As with any CME activity, these need to include discussion of the existing level of scientific evidence that supports the practices. However, education that advocates specific alternative therapies or teaches how to perform associated procedures, without scientific evidence or general acceptance among the profession that supports their efficacy and safety, cannot be certified for AMA PRA Category 1 Credit™. Content Validation The AANI, as an ACCME accredited provider, is responsible for validating the clinical content of CME activities that it provides. Specifically, (1) all the recommendations involving clinical medicine in a CME activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients and (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Disclaimer/Disclosures Disclaimer The primary purpose of the AAN/AANI program is to meet the educational needs of its members and address practice gaps by providing practice-oriented and scientifically based educational activities that will maintain and advance competence and performance in the field of neurology. A diversity of opinions exists in the medical field and the views of the conference faculty do not represent those of the AAN/AANI or constitute endorsement by the AAN/AANI. The AAN/AANI disclaims any and all liability for the claims that may result from the use or nonuse of information, publications, therapies, and/or services discussed during its conferences. The activities conducted, and content distributed, during the AAN/AANI conference are for educational purposes only and do not constitute or substitute professional medical advice, diagnosis, or treatment. EEGs, examples of neurologic exams, and other activities conducted during conferences are not for diagnostic or treatment purposes, do not establish a patient-physician relationship, do not constitute the practice of medicine, and are not conclusive as to the absence or presence of any health condition. The AAN/AANI does not recommend or endorse any specific physicians, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided is solely at participant’s own risk. The AAN/AANI is not liable to any participant or anyone else for any decision made or action taken by based on reliance upon the information provided during the program. AAN.com/21AM

CONFERENCE GUIDELINES Liability Participant assumes any and all liability associated with participation in AAN/AANI educational activities, and releases the American Academy of Neurology, the American Academy of Neurology Institute, and their contractors from any claims that may arise. The AAN/AANI is not liable for any claims whatsoever for personal injury, illness, death, or damages of any kind as a result of or caused by participation. Participation is voluntary. Faculty Disclosure of Commercial Relationships Consistent with the AAN/AANI and ACCME policies, faculty must disclose any relevant financial relationship with the manufacturer(s) discussed in their presentation, so that learners may form their own judgments about material discussed during the educational activity. Full disclosure of faculty’s commercial relationships will appear in the individual program materials or in the AAN Conferences mobile app. Unlabeled Use Disclosure The AANI requires all faculty members to disclose if a product is not labeled for the use being discussed or that the product is still investigational. Such disclosures will appear in the individual program materials. Grants Some education and scientific programs are supported in part by educational grants from commercial entities. Although educational grants are received, all programs are developed and implemented solely by the AANI/AAN. The terms, conditions, and purposes of the commercial support are documented in a written agreement between the AAN/AANI and commercial supporter. Disclosure of educational grants will occur in one or more of the following formats: through acknowledgment statements on the program materials, verbally from the podium, through acknowledgment statements on the program webpage, or an announcement at the start of the virtual video.

Meeting Policies Commitment to Inclusion, Diversity, Equity, Anti-racism, and Social Justice (IDEAS) The AAN is committed to intentional actions to be a fully inclusive, deliberately diverse, and anti-racist organization that respects and values our membership, our staff, and the communities we serve. We actively promote equity and social justice in neurology and the neurosciences. As part of this commitment, the AAN is working to ensure we provide a conference environment and educational programming that is fully inclusive, deliberately diverse, and anti-racist. If you have questions about these efforts, identify areas for improvement, or have concerns regarding attendee or staff behavior, please contact Member Services at (800) 879-1960, memberservices@aan.com, or Academy staff at registration@aan.com. Professional Conduct & Anti-harassment The AAN expects all meeting participants, including attendees, members, speakers, staff, contractors, vendors, and exhibitors, to behave respectfully, responsibly, and professionally towards each other, and to abide by the AAN’s Meetings Anti-harassment Policy (visit AAN.com/meetings-anti-harassment-policy), during the conference. The AAN is committed to providing a conference environment that is free from all forms of discrimination and harassment. Violations of this policy may be reported to Member Services at (800) 879-1960, memberservices@aan.com, or to Academy staff at registration@aan.com.

66 2021 AAN Annual Meeting

Authorization for Use of Image, Name, and Other Likeness By attending the AAN meeting or logging into the meeting’s website(s) or application(s) and engaging in any activities or interactive features, you agree that AAN/AANI and/or third parties authorized by AAN/AANI may photograph or record your likeness, image, name, voice, and/or words, and may publish, display, reproduce, copy, and distribute your likeness, image, name, voice, and/or words for promotional, educational, or membership activities worldwide in all forms of media now known or later developed, including but not limited to advertising, training, websites, presentations, and marketing materials. You further acknowledge that AAN/AANI and/or third parties authorized by AAN/AANI have the right, but not the obligation, to identify you in connection with such media by name and/or affiliation. No royalties will be payable in connection with this authorization or these uses. Social Media The American Academy of Neurology (AAN) encourages all AAN conference attendees to share their experience on social media using the official conference hashtag, #AANAM for the Annual Meeting, #AANSC for the Sports Concussion Conference, #AANFC for the Fall Conference, and #NeuroAPP for the Advanced Practice Provider Neurology Education Series. When doing so, please adhere to the following AAN Meetings Social Media Policies: • Photography and screenshots of presentations are permitted for personal use only. Photography or screenshots for commercial use are strictly prohibited.* • Do not disrupt fellow attendees. • Do not post any information or other material protected by copyright without the permission of the copyright owner. • Do not post confidential or identifiable patient information. • Do not post any material that is defamatory, abusive, profane, threatening, offensive, illegal, or violates any third party’s rights. • Videography, including live streaming, is strictly prohibited regardless of intended use. • Usage of the AAN logo or an AAN conference logo on social media is prohibited. The AAN has the right to ask any AAN conference attendee to remove a social post or to stop taking photos or recording video at any time. *Members of the press must follow the AAN Annual Meeting Press Policies. AAN Name and Logo Restrictions Exhibitions, marketing materials, sponsorship promotions, non-AAN events or programs, and non-AAN communications must not state or imply an endorsement by the AAN/ AANI or the AAN Annual Meeting/Regional Conferences events or misuse the AAN or the AAN Annual Meeting/AAN Regional Conferences logos or official conference names. No materials of any kind, including social media posts, outside of those produced and distributed by the AAN, will be allowed to use either the AAN logo or the AAN Annual Meeting/Regional Conferences logos, in part or in full, unless approved by the AAN in writing. Implied relationships or false representations of endorsements are strictly prohibited. Promotional references to official AAN meeting names are allowed to develop on-site traffic and awareness such as: • “Come see us at the 20XX AAN Annual Meeting” • “See you at the 20XX AAN Fall Conference” Cell Phones The AAN requests that participants turn cellular phones and pagers to vibrate mode for all conference programs.

AAN.com/21AM

CONFERENCE GUIDELINES Language The official language of AAN conferences is English except for content specifically developed in a different language. No simultaneous translation is available. No Smoking For the health and comfort of everyone, smoking, including the use of electronic cigarettes, is prohibited at AAN conferences and functions, which include all education and scientific activities and social functions, including virtual settings. Press and Media Room Only authorized journalists may use the Press and Media Room or access content at virtual meetings. Journalists must apply for press registration. For in-person meetings journalists must also provide proper credentials and check in at the Press and Media Room. For more information, email Renee Tessman at rtessman@aan.com or call (612) 928-6137. Accessibility The AAN strives to make our websites accessible. The AAN is committed to building and sustaining an inclusive organization that respects and values the diversity of our membership and the communities we serve. We are continually improving our digital assets to comply with current best practices and the accessibility guidelines. If you have questions regarding accessibility of the site and content, please contact registration@aan.com.

Registration Policy Registration Cancellation All sales for online programs including virtual conferences are final, nonrefundable, and nontransferable. Registration includes access to programs and materials on demand after the end of the conference. Login Sharing Registrations are for the specific individual registered and are not transferable. Misuse of login information, sharing login information, or any method of assisting unauthorized persons to gain access to any AAN Annual Meeting event is prohibited.

68 2021 AAN Annual Meeting

Introducing Vercise Genus™ from Boston Scientific – the only directional DBS system with Cartesia 3D. Combining Multiple Independent Current Control and unique directional capabilities with an ImageReady™ MR conditional portfolio, Vercise Genus is designed to offer unprecedented control for improved patient outcomes without compromise.

PRECISION TAKES SHAPE Vercise Genus™DBS System

*Note: Stimulation using multiple independent current control (MICC) with a Directional Lead is referred to as Cartesia 3D A System that includes the Vercise™ PC, Vercise Gevia™, or Vercise Genus™ IPG and Vercise Cartesia™ Directional Lead(s) forms the Vercise Directional System US Indications for Use: The Boston Scientific Deep Brain Stimulation Systems are indicated for use in: -Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa responsive Parkinson’s disease (PD) that are not adequately controlled with medication. -Bilateral stimulation of the internal globus pallidus (GPi) as an adjunctive therapy in reducing some of the symptoms of advanced levodopa responsive Parkinson’s disease (PD) that are not adequately controlled with medication. Contraindications, warnings, precautions, side effects: The Deep Brain Stimulation Systems or any of its components, is contraindicated for: Diathermy as either a treatment for a medical condition or as part of a surgical procedure, Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS) as the safety of these therapies in patients implanted with the Vercise™ DBS System has not been established, patients who are unable to operate the system, patients who are poor surgical candidates or who experience unsuccessful test stimulation. Patients implanted with Boston Scientific Deep Brain Stimulation Systems without ImageReady™ MRI Technology should not be exposed to Magnetic Resonance Imaging (MRI). Patients implanted with Vercise Gevia™ or Vercise Genus™ or Vercise DBS Lead-only system (before Stimulator is implanted) with ImageReady MRI Technology are Full Body MR Conditional only when exposed to the MRI environment under the specific conditions defined in ImageReady MRI Guidelines for Boston Scientific Deep Brain Stimulation Systems. Assess patients for the risks of depression and suicide. This assessment should consider both the risk of depression and suicide as well as the potential clinical benefits of DBS therapy. Monitor patients for new or worsening symptoms of depression, suicidal thoughts or behaviors, or changes in mood or impulse control and manage appropriately. Refer to the Instructions for Use provided with the Vercise DBS System or BostonScientific. com for potential adverse effects, warnings, and precautions prior to using this product. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician. Outside the US Indication for Use: CAUTION: The law restricts this device to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with the device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. Patients implanted with Boston Scientific Deep Brain Stimulation Systems without ImageReady™ MRI Technology should not be exposed to Magnetic Resonance Imaging (MRI). Patients implanted with Vercise Genus™ , Vercise Gevia™ or Vercise DBS Lead-only system (before Stimulator is implanted) with ImageReady MRI Technology are Full Body MR Conditional only when exposed to the MRI environment under the specific conditions defined in ImageReady MRI Guidelines for Boston Scientific Deep Brain Stimulation Systems. NM-957801-AA © 2021 by Boston Scientific Corporation or its affiliates. All rights reserved.

201 Chicago Avenue Minneapolis, MN 55415

AAN Excellence— Delivered Unconventionally Register now for the world’s premier neurology meeting— in a new, fully virtual format! Register by March 25 for the best rates

AAN.com/21AM April 17– April 22

2021 AAN Annual Meeting Science Program

Articles inside

Scientific Sessions

Abstracts of Distinction

Posters

Registration

Invited Science

Program Glossary

Register at AAN.com/21AM